

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
26 July 2001 (26.07.2001)

PCT

(10) International Publication Number
WO 01/53355 A1

- (51) International Patent Classification⁷: C07K 16/00
- (21) International Application Number: PCT/US01/02285
- (22) International Filing Date: 24 January 2001 (24.01.2001)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
09/490,320 24 January 2000 (24.01.2000) US
- (71) Applicant: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK [US/US];
West 116th Street and Broadway, New York, NY 10027 (US).
- (72) Inventor: CORNISH, Virginia, W.; 21 Claremont Avenue, #33, New York, NY 10027 (US).
- (74) Agent: WHITE, John, P.; Cooper & Dunham LLP, 1185 Avenue of the Americas, New York, NY 10036 (US).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:
----- with international search report
----- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 01/53355 A1

(54) Title: AN *IN VIVO* SCREEN USING CHEMICAL INDUCERS OF DIMERIZATION

(57) Abstract: The subject of the invention provides a compound having the formula: H1-X-B-Y-H2, wherein each of H1 and H2 may be the same or different and capable of binding to a receptor which is the same or different; wherein each of X and Y may be present or absent and if present, each may be the same or different spacer moiety; and wherein B is an enzyme cleavable moiety. Said compounds can be called chemical inducers of dimerization. This invention also provides a method of screening proteins for the ability to catalyze bond cleavage.

AN IN VIVO SCREEN USING CHEMICAL INDUCERS OF DIMERIZATION

This application is a continuation-in-part of U.S. Serial No. 09/490,320, filed January 24, 2000, the contents of which are
5 hereby incorporated by reference.

This invention has been made with government support under National Science Foundation grants CHE-9626981, CHE-9977402, and CHE-9984928. Accordingly, the U.S. Government has certain
10 rights in the invention.

Throughout this application, various publications are referenced by author or author and date. Full citations for these publications may be found listed alphabetically at the end of
15 the specification immediately preceding the claims. The disclosures of these publications in their entireties are hereby incorporated by reference into this application in order to more fully describe the state of the art as known to those skilled therein as of the date of the invention described and claimed
20 herein.

Field of Invention

The disclosed invention relates to the evolution of enzymes *in vivo*, and drug screening *in vivo* through the use of chemical
25 inducers of protein dimerization.

Background of the Invention

Initial efforts to design protein catalysts (enzymes) relied on the modification of individual proteins. (Kaiser; Knowles)
30 Despite some successes, (Wharton; Wilks; Hilvert; Imperiali; Johnson) protein engineering has proven to be difficult and has suggested that notions of how enzymes work may still be naive. Combinatorial techniques, which rely on generating and screening large pools of protein variants simultaneously, offer a
35 promising new approach to enzyme design. (DeGrado) Several straightforward methods exist for generating large libraries

-2-

($>10^{12}$) of proteins rapidly. (Reidharr-Olson; Eisenbeis; Wells; Zoller; Leung; Cadwell; Crameri; Zhang; Stemmer; Stemmer) Methodologies for identifying protein catalysts from libraries of proteins primarily have been based not on catalysis, but on
5 binding to a transition-state analog, (Wagner; Shokat) as in the case of catalytic antibodies (Schultz; Schultz; Hilvert; Posner) and phage-display (Baca). While antibodies clearly can catalyze a broad range of reactions, there are few reports (Jacobsen) that selections for binding can generate catalysts that rival
10 natural enzymes. *In vivo* complementation of essential enzymes, such as chorismate mutase and triosephosphate isomerase, offers a direct selection for catalysis but is limited to existing reactions. (Hermes; Kast) General screens and selections for catalysis are beginning to be reported. (DeGrado; Koltermann;
15 Pedersen)

Combinatorial techniques allow structure-activity relationships of enzymes to be amassed quickly. With the aid of powerful selections it should be possible to create synthetically useful
20 catalysts for pharmaceuticals and materials. However, as with proteins, it is difficult to design screens for non-protein catalysts.

Screens have been developed based on small-molecule inducible
25 gene expression. Several systems for small-molecule inducible gene expression have been developed to the point that they are integral to basic research. The discovery that the *lac* operon is induced by binding of lactose to the *lac* repressor led to the widespread use of isopropyl-b-D-thiogalactoside (IPTG) to induce
30 gene expression in bacteria. More recently it has been shown that by fusing the *tet* repressor to a eukaryotic transcription activation domain, gene expression in eukaryotes can be both negatively and positively regulated using tetracycline. (Gossen 1992, Gossen 1995) The demonstration that transgene expression
35 can be regulated with tetracycline in transgenic mice highlights

-3-

the utility of this system. In addition to the tetracycline-based system, ecdysone-, (No) estrogen-, (Braselman) and progesterone-regulated systems (Wang) have been reported.

5 An extension of these strategies resulted from studies of the mechanism of action of the immunosuppressants FK506 and rapamycin. (Rosen) It was found that the biological activity of both compounds resulted from the fact that they each dimerize two proteins, FKBP12 and calcineurin or FKBP12 and FRAP, that
10 otherwise do not interact. One portion of FK506 binds to FKBP12 and another to calcineurin. Based on this understanding, it was demonstrated that these molecules could be used to control protein oligomerization inside a cell.

15 Molecules such as FK506 are small molecule 'dimerizers' (sometimes referred to as chemical inducers of dimerization, CIDs) that activate the function of numerous proteins that regulate many important cellular processes. Dimerizers allow the functions of proteins to be explored even when small
20 molecule ligands are unknown. A limited number of such reagents have been synthesized that control the function of a much larger number of proteins (expressed as fusions of proteins of interest linked to a small molecule-responsive dimerization domain). See, e.g. Austin 1994, Belshaw 1996, Choi 1996, Crabtree 1996,
25 Diver 1997, Ho 1996, Holsinger 1995, Hung 1996, Klemm 1998, Liberles 1997, Pruschy 1994, Schreiber 1998, Spencer 1996, Spencer 1995, Spencer 1993, Stockwell 1998, and Yang 1998.

To generalize this approach, it was shown in 1993 that two FK506
30 molecules tethered via their C₂₁-allyl groups could oligomerize proteins fused to FKBP12. Specifically, several FK506 dimers termed "FK1012s" were shown to oligomerize the cytoplasmic domain of T-cell receptors when these domains were fused to the FK506-binding protein FKBP12. Since this initial paper, there
35 have been several important extensions of this work by Schreiber

and coworkers. Belshaw et al. reported in 1996 that two different proteins could be dimerized by tethering FK506 to cyclosporin. In 1997 Diver and Schreiber demonstrated a two-step synthesis of an FK1012 molecule based on recent olefin metathesis chemistry.

While this work with FK506 establishes a powerful new approach for manipulating cellular function with small molecules, optimized chemical handles that are more convenient to work with than FK506 are critical for realizing the potential of this approach. FK506 (Fig. 5B) is cell permeable and has excellent pharmacokinetic properties--as evidenced by its widespread use as an immunosuppressant. FK506, however, is not an ideal chemical handle. FK506 is not available in large quantities, coupling via the C₂₁ allyl group requires several chemical transformations including silyl protection of FK506, (Spencer; Pruschy) and FK506 is both acid and base sensitive. (Wagner 1998; Coleman 1989)

One very recent approach to replacing FK506 is to design synthetic ligands that also bind to FKBP12 with high affinity. In 1997 Amara et al. reported AP1510, a synthetic dimerizer that binds FKBP12 with high affinity and that can oligomerize proteins fused to FKBP12. Very recently a derivative of AP1510, "5S", was prepared that binds with high affinity to a FKBP12 mutant. (Clackson) This derivative is particularly interesting because it does not bind with high affinity to wild type FKBP12.

Recently a system has been reported, named the yeast three-hybrid system, for detecting ligand-receptor interactions *in vivo*. (Licitra, represented in Fig 2; U.S. Patent No. 5,928,868) This system is based on the principle that small ligand-receptor interactions underlie many fundamental processes in biology and form the basis for pharmacological intervention of human diseases in medicine. This system is adapted from the yeast two-hybrid system by adding a third synthetic hybrid

ligand. The feasibility of this system was demonstrated using as the hybrid ligand a dimer of covalently linked dexamethasone and FK506. The system used yeast expressing fusion proteins consisting of a) hormone binding domain of the rat glucocorticoid receptor fused to the LexA DNA-binding domain and b) FKBP12 fused to a transcriptional activation domain. When the yeast was plated on medium containing the dexamethasone-FK506 heterodimer, the reporter genes were activated. The reporter gene activation is completely abrogated in a competitive manner by the presence of excess FK506. Using this system, a screen was performed of a Jurkat cDNA library fused to the transcriptional activation domain in yeast in the presence of a methasone-FK506 heterodimer. The yeast in this system expressed the hormone binding domain of rat glucocorticoid receptor/DNA binding domain fusion protein. Overlapping clones of human FKBP12 were isolated. These results demonstrate that the three-hybrid system can be used to discover receptors for small ligands and to screen for new ligands to known receptors.

Other approaches, which do not rely on a readout based on alterations in genetic expression, have also been developed. WO 96/30540 (Tsien et al.) discloses a screen for β -lactamase activity that uses fluorescence resonance energy transfer as the indicator of β -lactamase activity. The degree of fluorescence in this screen depends on the level of β -lactamase activity. Detection of β -lactamase activity relies on detection of changes in the degree of fluorescence.

However, it has not heretofore been suggested to use small molecule induced protein dimerization to screen for catalysis *in vivo.*, and specifically, it has not been suggested to use an enzyme cleavable moiety to link two molecules to dimerize proteins.

This invention provides proteins *de novo* with prescribed binding


-6-

and catalytic properties and permits screening cDNA libraries based on biochemical function. Being able to understand and manipulate protein-small molecule interactions has broad implications for basic biomedical research and the pharmaceutical industry. Proteins engineered to have unique binding or catalytic properties have already proven useful as biomedical reagents, medical diagnostics, and even therapeutics. As with site-directed mutagenesis before it, randomization and screening techniques also offer an entirely new approach to understanding the molecular basis for recognition and catalysis. Technically, a high-throughput approach such as that disclosed here would speed-up the research because the activity of thousands of protein variants can be measured simultaneously. Practically, we believe that powerful screens in combination with existing randomization techniques will make it possible to take an existing protein fold and "evolve" it into an enzyme with a new function generating useful catalysts for the pharmaceutical and chemical industries. Intellectually, the ability to modify substrate specificity and catalytic activity offers a new standard for "understanding" how enzymes function. A powerful screen is also critical to the end goal of genome sequencing efforts-determining the function of each and every protein, bypassing decades of detailed biochemical and genetic experiments to unravel complex biochemical pathways. Since the screen is done in vivo and in both prokaryotes and eukaryotes, the methodology can be applied to functional genomics and drug discovery. A cDNA library can be screened for all enzymes that form or cleave a specific type of bond. A library of small molecules can be screened for its ability to inhibit a specific enzyme. The screen selects for cell permeability, compatibility with the cellular milieu, and inhibition of enzyme activity. The key to all of these applications is a robust screen for enzymatic activity such as that disclosed here.

-7-

Summary of the Invention

The subject invention provides a compound having the formula:



5

wherein each of H1 and H2 may be the same or different and capable of binding to a receptor which is the same or different; wherein each of X and Y may be present or absent and if present, each may be the same or different spacer moiety; and wherein B is an enzyme cleavable moiety. This invention also provides a method of screening proteins for the ability to catalyze bond cleavage, comprising the steps of:

10

a) providing a cell that expresses a pair of fusion proteins which upon dimerization change a cellular readout;

15

b) providing the compound of the invention which dimerizes the pair of fusion proteins, said compound comprising two portions coupled by a bond that is cleavable by the protein to be screened; and

20

c) screening for the cellular readout, wherein a change the cellular readout indicates catalysis of bond cleavage by the protein to be screened. Finally, the invention also provides a method of screening proteins for the ability to catalyze bond formation, comprising the steps of:

25

a) providing a cell that expresses a pair of fusion proteins which upon dimerization activate a cellular readout:

30

b) providing a first compound and a second compound, each being capable of binding to one of the pair of fusion proteins, said first and second compound comprising a portion through which the first and second compounds are coupled to form the inventive compound by the action of the bond forming protein to be screened; and

c) screening for the cellular readout, wherein a change in the cellular readout indicates catalysis of bond formation by the protein to be screened.

35

Description of the Figures

Figure 1. The selection strategy. Proteins V and W do not interact (A) until a BOND links the handles H1 and H2 (B). The selection can be run in the forward direction to select for BOND formation or the reverse direction to select for BOND cleavage.

Figure 2. The yeast three-hybrid system. The small molecule dexamethasone-FK506 (H1-H2) mediates the dimerization of the LexA-GR (glucocorticoid receptor) and B42-FKBP12 protein fusions. Dimerization of the DNA-binding protein LexA and the activation domain B42 activates transcription of the *lacZ* reporter gene.

Figure 3. The Model reaction. Cephalosporin hydrolysis by the 908R cephalosporinase.

Figure 4. DEX-CEPHEM-FK506 retrosynthesis. Cephem 1 is commercially available. DEX-CO₂H is prepared via oxidation of the C₂₀ α -hydroxy ketone; FK506-CO₂H, via a cross-metathesis reaction with the C₂₁ allyl group.

Figure 5. The chemical handles dexamethasone (A), FK506 (B), and methotrexate (C).

Figure 6. The dexamethasone-methotrexate molecules synthesized. The diamine linkers are commercially available and vary in length and hydrophobicity.

Figure 7. The Claisen rearrangement (A) and the Diels-Alder reaction (B) are both pericyclic reactions with six-membered transition states.

Figure 8. The retro-synthesis of the diene (A) and the dienophile (B). A Curtius rearrangement is used to introduce the carbamyl linkage to H1 in the diene. (Overman) A Stille coupling is used to introduce the alkyl linkage to H2 in the

dienophile. (Duchene) The cyclohexene product will be prepared through the cycloaddition of these two compounds.

Figure 9. Examples of DEX-DEX molecules synthesized to date.

5

Figure 10. DEX-MTX retrosynthesis.

Figure 11. Maps of the plasmids encoding the LexA-GR and B42-GR fusion proteins.

10

Figure 12. Dex-cephem-Mtx retro-synthesis.

Figure 13. Dex-Mtx protein dimerization system. A cell-permeable Dex-Mtx molecule is used to induce dimerization of LexA-GR and DHFR-B42 protein chimeras, activating transcription of a *lacZ* reporter gene.

15

Figure 14. Cell based assays. Yeast cells containing LexA-GR and B42-DHFR fusion proteins and the *lacZ* reporter gene are grown on X-gal plates with or without Dex-Mtx. Dex-Mtx dimerizes the fusion proteins, activating *lacZ* transcription, hydrolyzing the chromogenic substrate X-gal, and turning the cells blue. Dex-Mtx is added directly to the media in the x-gal plate. The assay takes two to five days.

20

Figure 15. X-gal plate assay of Dex-cephem-Mtx induced *lacZ* transcription. Yeast strains containing different LexA- and B42 chimeras, plus a *lacZ* reporter gene, were grown on X-gal indicator plates with or without Dex-cephem-MTX compounds: **A**, 1 μ M Dex-MTX; **B**, 10 μ M Dex-cephem-MTX; **C**, no small molecule. The strains that are dark (blue in original) even in the absence of small molecule (plate **C**) are positive controls on protein-protein interaction. The dark strains on plates **A** and **B** express LexA DHFR and B42-GR fusion proteins, and the white strains are negative controls, expressing only LexA and B42.

25
30
35

-10-

Figure 16A. Plate BTC4 grown on 4 different plates after 72 hours. One plate has no small molecule, so just the positive controls should be dark. The other three plates all have either 10 uM DM1, 10 uM D8M, or 10 uM D10M. **Figure 16B** is the plate map for plate BTC4.

Figure 17A. Plate BTC6 grown on 4 plates after 56 hours. Twotop plates contain no small molecule, and the bottom two plates contain 10 uM D10M. **Figure 17B** shows plate BTC6 grown on 2 plates after 60 hours. Both plates contain 1 uM D8M. **Figure 17C** shows the plate map for plate BTC6.

Figure 18. The β -galactosidase activity of strain V494Y using varying concentrations of D8M.

15

Figure 19. A screen for glycosidase activity. Dex-Mtx CIDs with cleavable oligosaccharide linkers used to assay the >3000 proteins in *S. cerevisiae* of unknown function for glycosidase activity. A yeast cDNA library is introduced into the selection strain. Only cells expressing active glycosidases cleave the oligosaccharide linker, disrupt *ura3* transcription, and survive in the presence of 5-FOA.

20

Figure 20. Proposed solid-phase synthesis of the Dex-Mtx glycosidase substrates. While the synthesis of Dex-(GlcNAc)₄-Mtx is shown, the synthesis is designed to allow the introduction of a variety of sugar monomers with both regio- and stereo-control.

25

-11-

Detailed Description of the Invention

The subject invention provides a compound having the formula:



5

wherein each of H1 and H2 may be the same or different and capable of binding to a receptor which is the same or different; wherein each of X and Y may be present or absent and if present, each may be the same or different spacer moiety; and wherein B

10

is an enzyme cleavable moiety.

In one embodiment, each of H1 and H2 is capable of binding to a receptor with a IC_{50} of less than 100 nM. In a preferred embodiment, each of H1 and H2 is capable of binding to a

15

receptor with a IC_{50} of less than 10 nM. In the most preferred embodiment, each of H1 and H2 is capable of binding to a receptor with a IC_{50} of less than 1 nM.

20

In one embodiment, B is capable of binding to an enzyme with an IC_{50} of less than 100 mM. In a further embodiment, B is capable of binding to an enzyme with an IC_{50} of less than 10 mM. In yet a further embodiment, B is capable of binding to an enzyme with an IC_{50} of less than 1 mM. In a preferred embodiment, B is capable of binding to an enzyme with an IC_{50} of less than 100 μ M,

25

more preferably, B is capable of binding to an enzyme with an IC_{50} of less than 10 μ M, and most preferably, B is capable of binding to an enzyme with an IC_{50} of less than 1 μ M.

30

In another embodiment, either of H1 and H2 are different, or X and Y are different.

Furthermore, B may be cleavable by an enzyme selected from the group of enzymes consisting of transferases, hydrolases, lyases, isomerases, and ligases.

35

-12-

The transferase is selected from the group consisting of, a one carbon transferase, an aldehyde or ketone transferase, an acyl transferase, a glycosyl transferase, an alkyl or aryl transferase, a N-containing group transferase, a P-containing group transferase, an S-containing group transferase, an O-containing group, and a Se-containing group transferase.

The hydrolase is selected from the group consisting of an ester hydrolase, a glycosidic hydrolase, an ether hydrolase, a peptide hydrolase, a C-N (non-peptide) hydrolase, an acid anhydride hydrolase, a C-C hydrolase, a P-N hydrolase, an S-N hydrolase, a C-P hydrolase, and an S-S hydrolase.

The lyase is selected from the group consisting of a C-C lyase, a C-O lyase, a C-N lyase, a C-S lyase, and a P-O lyase.

The isomerase is selected from the group consisting of racemases, epimerases, cis-trans isomerases, intra-oxidoreductases, intra-transferases (mutases), and intramolecular lyases.

The ligase is selected from the group consisting of a C-O ligase, a C-S ligase, a C-N ligase, a C-C ligase, and a P-O ligase.

In a preferred embodiment, B is an enzyme cleavable moiety selected from the group consisting of phosphodiester, glycoside, amide, ester, diester, aldol product, and acetate moiety. In a most preferred embodiment B represents an amide moiety, or a cephem moiety.

Each of H1 or H2 may be derived from a compound selected from the group consisting of steroids, hormones, nuclear receptor ligands, cofactors, antibiotics, sugars, enzyme inhibitors, and drugs.


-13-

Each of H1 and H2 may also represent a compound selected from the group consisting of dexamethasone, 3,5,3'-triiodothyronine, *trans*-retinoic acid, biotin, coumermycin, tetracycline, lactose, methotrexate, FK506, and FK506 analogs.


5

In a preferred embodiment, each of H1 and H2 is derived from the compound of Figure 5A, or the compound of Figure 5B, or the compound of Figure 5C.

- 10 The compound H1 - X - B - Y - H2 may be formed in a cell the reaction of a first compound having the formula:



- 15 with a second compound having the formula:



- 20 wherein B' and B'' are moieties that react to form B in the presence of an enzyme.

- The enzyme in this reaction may be selected from the group of enzymes consisting of transferases, lyases, isomerases, and ligases. Each one of the transferases, lyases, isomerases, and
25 ligases comprises groups as noted above.

This invention also provides a compound having the formula:



30

wherein H1 is capable of binding to a receptor;
wherein X is a spacer moiety which may be present or absent; and
wherein B' is a moiety capable of binding to an enzyme.


- 35 H1 should be capable of binding to a receptor with a IC₅₀ of less than 100 nM, preferably H1 is capable of binding to a receptor

-14-

with a IC_{50} of less than 10 nM, more preferably H1 is capable of binding to a receptor with a IC_{50} of less than 1 nM.

5 B' should be capable of binding to an enzyme with an IC_{50} of less than 100 mM, preferably B' is capable of binding to an enzyme with an IC_{50} of less than 50 mM, more preferably B' is capable of binding to an enzyme with an IC_{50} of less than 1 mM, yet more preferably B' is capable of binding to an enzyme with an IC_{50} of less than 100 μ M, yet more preferably B' is capable of binding
10 to an enzyme with an IC_{50} of less than 10 μ M, and most preferably B' is capable of binding to an enzyme with an IC_{50} of less than 1 μ M.

15 The compound H1-X-B' may react with a moiety which has the formula:



20 wherein H2 is capable of binding to a receptor; wherein Y is a spacer moiety which may be present or absent; wherein B'' is a moiety that reacts with B' in the presence of the enzyme.

This invention also provides a complex comprising the compound having the formula H1 - X - B - Y - H2 complexed to an enzyme.

25 In the complex, the compound is capable of binding to the enzyme with an IC_{50} of less than 100 mM, preferably with an IC_{50} of less than 10 mM, more preferably with an IC_{50} of less than 1 mM, yet more preferably with an IC_{50} of less than 100 μ M, yet more
30 preferably with an IC_{50} of less than 10 μ M, and most preferably with an IC_{50} of less than 1 μ M.

This invention also provides a complex comprising the compound having the formula H1-X-B' complexed to an enzyme.

35

-15-

In this complex, the compound is capable of binding to the enzyme with an IC_{50} of less than 100 mM, preferably with an IC_{50} of less than 10 mM, more preferably with an IC_{50} of less than 1 mM, yet more preferably with an IC_{50} of less than 100 μ M, yet
5 more preferably with an IC_{50} of less than 10 μ M, and most preferably with an IC_{50} of less than 1 μ M.

This invention also provides a composition comprising the compound having the formula $H1 - X - B - Y - H2$, or the compound
10 having the formula $H1-X-B'$. The composition may further comprise an enzyme.

This invention also provides a composition comprising the complex of the compound having the formula $H1 - X - B - Y - H2$
15 with an enzyme, or of the compound having the formula $H1-X-B'$ with an enzyme.

This invention also provides a method of screening proteins for the ability to catalyze bond cleavage, comprising the steps of:
20 a) providing a cell that expresses a pair of fusion proteins which upon dimerization change a cellular readout;
b) providing a compound which dimerizes the pair of fusion proteins, said compound comprising two portions coupled by a bond that is cleavable by the protein to be screened; and
25 c) screening for the cellular readout, wherein a change the cellular readout indicates catalysis of bond cleavage by the protein to be screened.

The cellular readout may be reconstitution of enzymatic
30 activity.

The method further provides a cell that contains a gene which is activated by a dimerized pair of fusion proteins. The pair of fusion proteins are dimerized by a compound having the
35 formula $H1 - X - B - Y - H2$.

-16-

The cellular readout may also be gene transcription, such that a decrease of gene transcripton indicates catalysis of bond cleavage by the protein to be screened.

- 5 The gene transcribed may be *lacZ*, *leu2*, *ura3*, *his3*, or *trp*.

This invention also provides a method of screening proteins for the ability to catalyze bond formation, comprising the steps of:

- 10 a) providing a cell that expresses a pair of fusion proteins which upon dimerization activate a cellular readout:
b) providing a first compound and a second compound, each being capable of binding to one of the pair of fusion proteins, said first and second compound comprising a portion through which the first and second compounds are coupled by the action
15 of the bond forming protein to be screened; and
c) screening for the cellular readout, wherein a change in the cellular readout indicates catalysis of bond formation by the protein to be screened.

- 20 The cellular readout may be enzyme activity.

The method further comprises providing a cell that contains a gene which is activated by the dimerized pair of fusion proteins.

25

The cellular readout may be gene transcription, such that an increase in gene transcription indicates catalysis of bond formation by the protein to be screened.

- 30 In this method, either the first or the second compound is the compound having the formula H1-X-B'.

In either of the methods of this invention, the cell is selected from the group consisting of yeast, bacteria or mammalian. The
35 cell may be selected from the group consisting of *S. cerevisiae*, and *E. coli*.

-17-

The pair of fusion proteins is the rat glucocorticoid receptor (rGR2), or binding domain thereof, fused to *LexA*, and FKBP12 fused to the B42 transcriptional activation domain.

- 5 The pair of fusion proteins may also be the dihydrofolate reductase (DHFR), or binding domain thereof, fused to *LexA*, and FKBP12 fused to the B42 transcriptional activation domain.

- 10 The pair of fusion proteins may further be dihydrofolate reductase (DHFR), or binding domain thereof, fused to *LexA*, and the rat glucocorticoid receptor (rGR2), or binding domain thereof, fused to the B42 transcriptional activation domain.

- 15 The pair of fusion proteins may yet further be the rat glucocorticoid receptor (rGR2), or binding domain thereof, fused to *LexA*, and dihydrofolate reductase (DHFR), or binding domain thereof, fused to the B42 transcriptional activation domain.

- 20 Finally, the pair of fusion proteins may yet even further be dihydrofolate reductase (DHFR), or binding domain thereof, fused to *LexA*, and the rat glucocorticoid receptor (rGR2), or binding domain thereof, fused through a 6-Glycine linker to the B42 transcriptional activation domain.

- 25 In either method the protein to be screened is an enzyme selected from the group of enzyme classes consisting of transferases, hydrolases, lyases, isomerases and ligases.

- 30 In either method, the screening is performed by Fluorescence Associated Cell Sorting (FACS), or gene transcription markers selected from the group consisting of Green Fluorescence Protein, *LacZ*- β -galactosidases, luciferase, antibiotic resistant β -lactamases, and yeast markers.

- 35 This invention also provides a method of screening a compound

-18-

for the ability to inhibit an enzyme comprising:

screening for activity of the enzyme by the method disclosed herein, and obtaining cells which express an active enzyme, and

5 contacting the cells with the drug to be screened, wherein a change in the transcription of the reporter gene within the cell after contact with the drug indicates inhibition of the enzyme by the drug.

10 This invention also provides a drug for the inhibition of an enzyme selected by this method.

 This invention further provides a method of evolving a protein with a new catalytic activity comprising screening proteins
15 derived from a library of proteins which are mutants of a known protein, using either of the screening methods provided by this invention.

 Thus, this invention also provides a protein with new catalytic
20 activity evolved by this method.

 This invention also provides a method of evolving an enzyme with a new substrate specificity comprising screening enzymes derived from a library of enzymes which are mutants of an enzyme with
25 known substrate specificity, using either of the screening methods provided by this invention.

 Thus, this invention provides an engineered enzyme having new substrate specificity evolved by this method.

30 This invention also provides a method for evolving an enzyme that functions with a cofactor which is different from the cofactor the natural coenzyme uses, comprising:

 evolving mutants of the natural coenzyme; and
35 screening the mutants of the natural coenzyme in the presence of a cofactor different from the cofactor of the


natural enzyme, using either of the screening methods provided by this invention.

Thus, this invention provides an engineered enzyme that
5 functions with a cofactor which is different from cofactors the enzymes naturally uses evolved by this method.

The foregoing embodiments of the subject invention may be accomplished according to the guidance which follows. Certain
10 of the foregoing embodiments are exemplified. Sufficient guidance is provided for a skilled artisan to arrive at all of the embodiments of the subject invention.

Also disclosed is a compound having the formula:

15




wherein H1 is methorexate or an analog thereof;

wherein H2 is capable of binding to a receptor, and

wherein Y is a moiety providing a covalent linkage between H1
20 and H2, which may be present or absent, and when absent, H1 is covalently linked to H2. H2 may be Dex or an analog thereof. When H1 is Mtx, then H2 may be Dex or an analog thereof.

The compound may also have the formula Mtx-Y-H2, and the formula
25 Dex-Y-Mtx. The compound may also have the formula:

30




35


-20-

In the compound, wherein H2 may be capable of binding to a receptor with an IC₅₀ of less than 100 mM; or an IC₅₀ of less than 10 mM; or an IC₅₀ of less than 1 mM; or an IC₅₀ of less than 100 μM; or an IC₅₀ of less than 10 μM; or an IC₅₀ of less than 1 μM; or an IC₅₀ of less than 100 nM; or an IC₅₀ of less than 10 nM; or an IC₅₀ of less than 1 nM.


The compound may have the formula:



10 The compound may also have the formula:




The compound may also have the formula:




-21-

The compound may also have the formula:



The compound may also have the formula:

5



10

-22-

Also disclosed is a complex between the compound having the formula H1-Y-H2 and a fusion protein which comprises a binding domain capable of binding to methotrexate, wherein H1 of the compound binds to the binding domain of the fusion protein. The binding domain may be that of the DHFR receptor.

In complex, H1 is capable of binding to the binding domain of the fusion protein with an IC₅₀ of less than 100 nM; or an IC₅₀ of less than 10 nM; or an IC₅₀ of less than 1 nM; or an IC₅₀ of less than 100 pM; or an IC₅₀ of less than 10 pM; or an IC₅₀ of less than 1 pM.

In the complex, the fusion protein may be DHFR-LexA, or DHFR-B42.

Also disclosed is a cell comprising the complex.

Also disclosed is a method of dimerizing two fusion proteins inside a cell using the compound having the formula H1-Y-H2, comprising the steps of a) providing a cell that expresses a first fusion protein which comprises a binding domain that binds to H1 and second fusion protein which comprises a binding domain that binds to H2, and b) contacting the compound having the formula H1-Y-H2 with the cell so as to dimerize the two fusion proteins.

In the method, the first fusion protein or the second fusion protein may be DHFR-(DNA-binding domain); or the first fusion protein or the second fusion protein may be DHFR-(transcription activation domain).

Also in the method, the first fusion protein or the second fusion protein may be DHFR-LexA; or first fusion protein or the second fusion protein is DHFR-B42.

35

-23-

Also disclosed is a method for identifying a molecule that binds a known target in a cell from a pool of candidate molecules, comprising:

5 (a) covalently bonding each molecule in the pool of candidate molecules to a methotrexate moiety or an analog of methotrexate to form a screening molecule;

10 (b) introducing the screening molecule into a cell which expresses a first fusion protein comprising a binding domain capable of binding methotrexate, a second fusion protein comprising the known target, and a reporter gene wherein expression of the reporter gene is conditioned on the proximity of the first fusion protein to the second fusion protein;

15 (c) permitting the screening molecule to bind to the first fusion protein and to the second fusion protein so as to activate the expression of the reporter gene;

(d) selecting which cell expresses the reporter gene; and

(e) identifying the small molecule that binds the known target.

20 In the method, the cell may be selected from the group consisting of insect cells, yeast cells, mammalian cell, and their lysates. The first or the second fusion protein may comprise a transcription module selected from the group consisting of a DNA binding protein and a transcriptional activator. Alos, the molecule may be obtained from a
25 combinatorial library.

Steps (b)-(e) of the method may be repeated iteratively in the presence of a preparation of random small molecules for competitive binding with the hybrid ligand so as to identify a
30 molecule capable of competitively binding the known target.

Also disclosed is a method for identifying a protein target to

-24-

which a molecule is capable of binding, comprising:

5 (a) providing a screening molecule comprising a methotrexate moiety or an analog of methotrexate covalently bonded to a ligand which has a specificity for an unknown protein target;

10 (b) introducing the screening molecule into a cell which expresses a first fusion protein comprising a binding domain capable of binding methotrexate, a second fusion protein comprising the unknown protein target, and a reporter gene wherein expression of the reporter gene is conditioned on the proximity of the first fusion protein to the second fusion protein;

15 (c) permitting the screening molecule to bind to the first fusion protein and to the second fusion protein so as to activate the expression of the reporter gene;

(d) selecting which cell expresses the reporter gene; and

(e) identifying the unknown protein target.

20 In the method, the unknown protein target may be encoded by a DNA from the group consisting of genomicDNA, cDNA and syntheticDNA. The ligand may have a known biological function.

-25-

Evolution of a Novel enzyme

We begin with an evolution of a novel enzyme. While it is desirable to evolve novel enzymes using combinatorial techniques, the major barrier to applying combinatorial techniques to catalyst design is the lack of selections that are both general and depend directly on catalysis. The following disclosure provides a selection based on *in vivo* assays for protein-protein interactions, generally represented in Fig. 1.

10 Selection Strategy

The selection strategy is based on existing methods for controlling protein dimerization *in vivo* using small molecules (Fig. 1). Several "chemical inducers of dimerization" have been reported showing that protein dimerization can be bridged by small molecules. (Spencer; Crabtree) Moreover, a number of techniques exist for translating the dimerization of two proteins to an *in vivo* screen or selection. (Hu 1990; Hu 1995; Fields; Gyuris; Johnsson; Rossi; Karimova) Taken together, this work establishes that it is feasible to use a small molecule H1-H2 to dimerize two fusion proteins, reporter V-H1 receptor and reporter W-H2 receptor, generating a cellular read-out.

It has also been established that enzyme activity can be monitored, *in vivo*, and new enzymes can be screened for, *in vivo*, by splitting peptides. (Baum 1990, Smith 1991, Kamada 1998, Hawkins 1999).

Disclosed is the dimerization of two proteins via covalent coupling of H1 and H2 as the basis for a general selection for catalysis. That is, the small-molecule H1-X-BOND-Y-H2 represented in Fig. 1 is used to mediate protein dimerization and hence a cellular signal. Then the enzyme that catalyzes either BOND formation or BOND cleavage is selected. The catalyst is tied to the cellular "read-out" because only cells containing an active enzyme have the desired phenotype.

-26-

The strategy is both general and a direct selection for catalysis. The selection can be applied to a broad range of reactions because protein dimerization depends only on H1 and H2, not X, Y, or the BOND being formed or cleaved. It is a
5 direct selection for catalysis because covalent coupling of H1 and H2 is necessary for protein dimerization. Also, unlike catalytic antibodies, this strategy does not limit the starting protein scaffold.

Preparation and design of handles "H1" and "H2"

Ideally, a chemical handle should bind its receptor with high affinity (≤ 100 nM), cross cell membranes yet be inert to modification or degradation, be available in reasonable quantities, and present a convenient side-chain for routine chemical derivatization that does not disrupt receptor binding. Again, we build from DEX-FK506 (H1-H2) mediated dimerization of LexA-rGR and B42-FKBP12 (Fig. 2) (Licitra; U.S. Patent No. 5,928,868).

10

Dexamethasone (DEX) is a very attractive chemical handle H1 (Fig. 5A). DEX binds rat glucocorticoid receptor (GR) with a K_D of 5 nM, (Chakraborti) can regulate the *in vivo* activity and nuclear localization of GR fusion proteins (Picard), and is commercially available. Affinity columns for rGR have been prepared via the C_{20} α -hydroxy ketone of dexamethasone. (Govindan; Manz)

15

The antibacterial and anticancer drug methotrexate (MTX) is used in place of FK506 as the chemical handle H2 (Fig. 5B, 5C). FK506 is not available in large quantities, coupling via the C_{21} allyl group requires several chemical transformations including silyl protection of FK506, (Spencer; Pruschy) and FK506 is both acid and base-sensitive. (Wagner; Coleman) MTX, on the other hand, is commercially available and can be modified selectively at its γ -carboxylate without disrupting dihydrofolate reductase (DHFR) binding. (Kralovec; Bolin) Even though MTX inhibits DHFR with μ M affinity, (Bolin; Sasso) both *E. coli* and *S. cerevisiae* grow in the presence of MTX when supplemented with appropriate nutrients. (Huang)

25

30

The ability of DEX-MTX to mediate the dimerization of LexA-rGR and B42-DHFR is tested by (1) synthesis of a series of DEX-MTX molecules with simple diamine linkers (Fig. 6); and (2) showing that DEX-MTX can dimerize LexA-rGR and B42-DHFR based on *lacZ* transcription and that both DEX and MTX uncoupled, can,

35

-28-

competitively disrupt this dimerization. Cell permeable chemical handles that can be prepared readily and that are efficient at inducing protein dimerization not only are essential to the robustness of this selection methodology but
5 also should find broad use as chemical inducers of protein dimerization.

Dexamethasone (DEX) and the glucocorticoid receptor (GR) present a particularly attractive chemical handle/ receptor pair.
10 Dexamethasone is the cortical steroid with the highest affinity for the rat Glucocorticoid Receptor. The rGR binds DEX with a K_D of 5 nM, and mutants of rGR have been isolated with up to 10-fold higher affinity for DEX. (Chakraborti) The steroid dexamethasone has been used extensively as a cell-permeable
15 small molecule to regulate the *in vivo* activity and nuclear localization of GR fusion proteins. (Picard) This work firmly establishes that DEX is cell permeable and is not modified or broken down in the cell. Recently, there has been one report of a yeast "three-hybrid" system in which a GR-DNA-binding
20 protein fusion and a FKBP12-transcription activation domain fusion could be dimerized by the small molecule DEX-FK506 (Fig. 2). Dexamethasone is commercially available in large quantities. Affinity columns for rGR have been prepared via oxidation of the C₂₀ α -hydroxy ketone of DEX to the
25 corresponding carboxylic acid. (Govindan, Manz)


Methotrexate (MTX) inhibition of dihydrofolate reductase (DHFR) is one of the textbook examples of high-affinity ligand binding. The interaction between MTX and DHFR is extremely well
30 characterized in the literature both biochemically and structurally. DHFR is a monomeric protein and binds MTX with picomolar affinity. (Bolin, Sasso) Even though MTX inhibits DHFR with such high affinity, both *E. coli* and *S. cerevisiae* grow in the presence of MTX when supplemented with appropriate
35 nutrients. (Huang) The ability of MTX to serve both as an antibacterial and an anticancer agent is clear evidence that MTX

-29-

has excellent pharmacokinetic properties. MTX is known to be imported into cells via a specific folate transporter protein. MTX is commercially available and can be synthesized readily from simple precursors. MTX can be modified selectively at its g-carboxylate without disrupting its interaction with DHFR. (Kralovec, Bolin) There are several examples reported where MTX has been modified via its g-carboxylate to prepare affinity columns and antibody conjugates.


Given the number of cellular pathways that depend on cascades of dynamic protein-protein interactions, the ability to regulate protein oligomerization *in vivo* with small molecules should have broad applications in medicine and basic science. The key to realizing the potential of these small molecules both for the catalysis screen in the laboratory and for these biomedical applications is developing H1-H2 molecules that can be prepared readily and are efficient at inducing protein dimerization *in vivo*.

Other handles H1 and H2 may be for example, steroids, such as the Dexamethasone used herein; enzyme inhibitors, such as Methotrexate used herein; drugs, such as KF506; hormones, such as the thyroid hormone 3,5,3'-triiodothyronine (structure below)



Ligands for nuclear receptors, such as retinoic acids, for example the structure below


-30-



5

General cofactors, such as Biotin (structure below)

10



15 and antibiotics, such as Coumermycin (which can be used to induce protein dimerization according to Perlmutter et al., Nature **383**, 178 (1996)).

Derivative of the mentioned compounds with groups suitable for
20 linking without interfering with receptor binding can also be used.

It has been found that the combination of the Mtx moiety containing CID with DHFR binding domain containing fusion
25 protein is a highly useful and widely applicable. Mtx and the DHFR receptor present a particularly attractive chemical handle/receptor pair. In addition to having a picomolar binding affinity, the complex of an Mtx moiety and the DHFR binding domain is extremely well characterized. The excellent
30 pharmacokinetic properties of Mtx make it an ideal moiety to be used in procedures where ease of importation into cells is required.

Linking H1 and H2 through a linker

35 To illustrate how the handles H1 and H2 may be linked together, several of the DEX-DEX compounds that have been synthesized to

-31-

date are shown in Figure 9. The linkers are all commercially available or can be prepared in a single step. The linkers vary in hydrophobicity, length, and flexibility. a series of DEX-DEX molecules have been synthesized (Fig. 9). The DEX-DEX molecules shown in Figure 9 were prepared from Dexamethasone and the corresponding diamines. The C₂₀ α -hydroxy ketone of dexamethasone was oxidized using sodium periodate to the corresponding carboxylic acid in quantitative yield as described. The diamines are commercially available. The diamine corresponding to DEX-DEX 2 was prepared from *a,a'*-dibromo-*m*-xylene and aminoethanethiol and used crude. The diamines were coupled to the carboxylic acid derivative of dexamethasone using the peptide-coupling reagent PyBOP under standard conditions in 60-80% yield.

We have synthesized a DEX-MTX molecule. The retrosynthesis is shown in Figure 10. The synthesis is designed to be modular so that we can easily bring in a variety of linkers in one of the final steps as the dibromo- or diiodo-derivatives. For synthetic ease, the glutamate residue has been replaced with homocysteine. This replacement should be neutral because there is both biochemical and structural evidence that the *g*-carboxylate of methotrexate can be modified without disrupting DHFR binding. The final compound has been synthesized in 12 steps in 1.3% overall yield. Also synthesized are analogous compounds where the *a,a'*-dibromo-*m*-xylene linker is replaced with 1,5-diiodopentane or 1,10-diiododecane. A similar route is used to prepare MTX-MTX molecules.

30 Design of the protein chimeras

The second important feature is the design of the protein chimeras. The yeast two-hybrid assay was chosen in the examples because of its flexibility. Specifically, the Brent two-hybrid system is used, which uses LexA as the DNA-binding domain and B42 as the transcription activation domain. The Brent system

-32-

is one of the two most commonly used yeast two-hybrid systems. An advantage of the Brent system is that it does not rely on Gal4 allowing use of the regulatable Gal promoter. *lacZ* under control of 4 tandem LexA operators are used as the reporter gene. Initially, we chose to make simple LexA-GR and DHFR and B42-GR and DHFR fusion proteins that do not depart from the design of the Brent system. In the Brent system, the full length LexA protein which includes both the N-terminal DNA-binding domain and the C-terminal dimerization domain is used. The B42 domain is a monomer. The C-terminal hormone-binding domain of the rat Glucocorticoid Receptor is chosen because this domain was shown to work previously in the yeast three-hybrid system reported by Licitra, et al. Both the *E. coli* and the murine DHFRs are used because these are two of the most well characterized DHFRs. The *E. coli* protein has the advantage that methotrexate binding is independent of NADPH binding.

Construction of the LexA- and B42-receptor fusions is facilitated by the availability of commercial vectors for the Brent two-hybrid system. These vectors are shuttle vectors that can be manipulated both in bacteria and yeast. The LexA chimera is under control of the strong, constitutive alcohol dehydrogenase promoter. The B42 chimera is under control of the strong, regulatable galactose promoter. Both the GR and the two DHFR genes were introduced into the multiple cloning sites of the commercial LexA and B42 expression vectors using standard molecular biology techniques. The GR fusions are shown in Figure 11. The available restriction sites result in a three amino acid spacer between the two proteins in both the GR and the DHFR constructs. The plasmids encoding the LexA- and B42-fusion proteins were introduced in all necessary combinations into *S. cerevisiae* strain FY250 containing a plasmid encoding the *lacZ* reporter plasmid.

-33-

Three initial assays are conducted: (1) toxicity of the ligand and receptor, (2) cell permeability of the H1-H2 molecules as judged by competition in the yeast three-hybrid system, and (3) activation of *lacZ* transcription by the H1-H2 molecule as judged by X-gal hydrolysis. All of these experiments have been done as plate assays. The toxicity of the ligand and receptor is judged simply by seeing if either induction of the receptor fusions or application of the ligand to the plate impairs cell growth. Cell permeability is assessed based on the ability of an excess of DEX-DEX or DEX-MTX to disrupt DEX-FK506 induction of *lacZ* transcription in the yeast three-hybrid system. An excess of DEX-DEX or DEX-MTX should bind to all of the available LexA-GR chimera and disrupt transcription activation so long as the molecule is cell permeable and retains the ability to bind to GR. Effective protein dimerization by H1-H2 is assayed by activation of *lacZ* transcription.

The DEX-DEX molecules were tested by all three assays. Preliminary results show that neither DEX nor GR are toxic. Under the conditions tried thus far, none of the DEX-DEX molecules tested are efficient at protein dimerization as judged by the *lacZ* transcription assay. We have been able to repeat the yeast three-hybrid result - activation of *lacZ* transcription using DEX-FK506, in our lab. DEX-DEX 1 and DEX-DEX 5 have been assayed for cell permeability. At 1 μ M DEX-FK506 and 10 μ M DEX-DEX, DEX-DEX 1, but not DEX-DEX 5, decreases *lacZ* transcription in the yeast three-hybrid system by 50%. These results show that a DEX-DEX molecule is cell permeable and retains the ability to bind to GR.

The protein chimeras can be varied in four ways: (1) invert the orientation of the B42 activation domain and the receptor; (2) introduce tandem repeats of the receptor; (3) introduce (GlyGlySer)_n linkers between the protein domains; (4) vary the DNA-binding domain and the transcription activation domain. We

-34-

expect these experiments to be carried out over the next two years. The motivation for these experiments is that many different protein fusions have been reported in the literature and these types of modifications have been shown to be critical in these previous experiments. We have designed each of these experiments so that multiple variations can be made simultaneously. Inverting the orientation so that the receptor, not B42, is N-terminal is trivial. We will construct a generic vector that can be used with different receptors. Likewise, since several different DNA-binding domains and activation domains have been used with the yeast two-hybrid system, it is not difficult to vary these domains.


An approach to introducing tandem repeats of the receptor and (GlyGlySer)_n linkers that allows us to make multiple constructs simultaneously is provided. As illustrated for GR, the approach to making tandem repeats of the receptor is to use restriction enzymes with compatible cohesive ends (Fig. 14). The same PCR product can then be used to introduce each receptor unit. By including a BamHI restriction site immediately 5' to the gene encoding GR, a series of (GlyGlySer)_n linkers can be introduced essentially as described. This approach relies on the fact that the BamHI site, GGA-TCC, encodes Gly-Ser. This combined approach will allow for the construction of multiple protein chimeras simultaneously. Since a lacZ screen is used, all of these constructs can be assayed simultaneously.

Design of Linkers that respond to specific enzymatic activity


The linkers, X-B-Y, may be designed according to the type of enzymatic activity desired. The linkers are readily synthesized by known techniques. For example, the following linkers may be used:

- 1) Glycosidase bond, which may be cleaved by a Glycosidase enzyme and formed by a Glycosyltransferase enzyme


-35-



\rightleftharpoons
 Glycosyltransferase Glycosidase




2) Phosphodiester bond.




5 3) Amide bond, which may be cleaved by protease and formed by peptidase or transpeptidase. An example of such a bond is a cephem bond shown in Figures 4 and 12.

10 4) Ester bond.

-36-



- 15 5) Aldol product bond, which is cleaved by a retro-aldolase and formed by Aldolase.



20 Other Enzymes and classes of enzymes

With a linker that contains an appropriate bond, the subject invention can screen derivatives of a large classes of enzymes.

A variety of enzymes and enzymes classes are listed on the World Wide Web beginning at prowl.rockefeller.edu/enzymes/enzymes.htm. All enzymes are given an Enzyme Commission (E.C.) number allowing it to be uniquely identified. E.C. numbers have four fields separated by periods, "a.b.c.d". The left-hand-most field represents the most broad classification for the enzyme. The next field represents a finer division of that broad category. The third field is adds more detailed information and the fourth field defines the specific enzyme. Thus, in the "a" field the classifications are oxidoreductases, transferases, hydrolases, lyases, isomerases, and ligases. Each of these "a" classifications are then further separated into corresponding "b", each of which in turn is separated into corresponding "c" classifications, which are then further separated into corresponding "d" classes.

The subclasses of oxidoreductases are, for example:

1.1 CH-OH, 1.2 aldehyde or oxo, 1.3 CH-CH, 1.4 CH-NH₂, 1.5 CH-NH, 1.6 NADH OR NADPH, 1.7 other N-containing, 1.8 sulfur, 1.9 heme, 1.10 diphenols and related, 1.11 peroxidases, 1.12 hydrogen, 1.13 single donors + O₂, 1.14 paired donors + O₂, 1.15 superoxide radical, 1.16 oxidizing metal ions, 1.17 CH₂, 1.18 reduced ferredoxin, and 1.19 reduced flavodoxin.

The subclasses of transferases are, for example:

2.1 one carbon, 2.2 aldehydes or ketones, 2.3 acyl, 2.4 glycosyl, 2.5 alkyl or aryl, 2.6 N-containing, 2.7 P-containing, 2.8 S-containing, and 2.9 Se-containing.

The subclasses of hydrolases are, for example:

3.1 ester, 3.2 glycosidic, 3.3 ether, 3.4 peptide, 3.5 C-N (non-peptide), 3.6 acid anhydride, 3.7 C-C, 3.8 C-halide, 3.9 P-N, 3.10 S-N, 3.11 C-P, and 3.12 S-S.

The subclasses of lyases are, for example:

4.1 C-C, 4.2 C-O, 4.3 C-N, 4.4 C-S, 4.5 C-halide, and 4.6 P-O.

The subclasses of isomerase are, for example:

- 5.1 racemases and epimerases, 5.2 cis-trans isomerases, 5.3
intra-oxidoreductases, 5.4 intra-transferases (mutases), and 5.5
5 intramolecular lyases.

The subclasses of ligases are, for example:

- 6.1 C-O, 6.2 C-S, 6.3 C-N, 6.4 C-C, and 6.5 P-ester.

- 10 Each of the mentioned classes is further separated into sub,
sub-classes, i.e. the "c" level, and then the "d" level.

- Moreover, new enzymes are discovered and are intended to be
included within the scope of this invention, which is itself
15 designed to evolve or discover such new enzymes.

Design of reporter genes

- A reporter gene assay measures the activity of a gene's
promoter. It takes advantage of molecular biology techniques,
20 which allow one to put heterologous genes under the control of
a mammalian cell (Gorman, C.M. et al., Mol. Cell Biol. 2: 1044-
1051 (1982); Alam, J. And Cook, J.L., Anal. Biochem. 188: 245-
254, (1990)). Activation of the promoter induces the reporter
gene as well as or instead of the endogenous gene. By design
25 the reporter gene codes for a protein that can easily be
detected and measured. Commonly it is an enzyme that converts
a commercially available substrate into a product. This
conversion is conveniently followed by either chromatography or
direct optical measurement and allows for the quantification of
30 the amount of enzyme produced.

- Reporter genes are commercially available on a variety of
plasmids for the study of gene regulation in a large variety of
organisms (Alam and Cook, *supra*). Promoters of interest can be
35 inserted into multiple cloning sites provided for this purpose

-39-

in front of the reporter gene on the plasmid (Rosenthal, N., *Methods Enzymo.* 152: 704-720 (1987); Shiau, A. and Smith, J.M., *Gene* 67: 295-299 (1988)). Standard techniques are used to introduce these genes into a cell type or whole organism (e.g.,
5 as described in Sambrook, J., Fritsch, E.F. and Maniatis, T. Expression of cloned genes in cultured mammalian cells. In: *Molecular Cloning*, edited by Nolan, C. New York: Cold Spring Harbor Laboratory Press, 1989). Resistance markers provided on
10 the plasmid can then be used to select for successfully transfected cells.

Ease of use and the large signal amplification make this technique increasingly popular in the study of gene regulation. Every step in the cascade DNA --> RNA --> Enzyme --> Product -->
15 Signal amplifies the next one in the sequence. The further down in the cascade one measures, the more signal one obtains.

In an ideal reporter gene assay, the reporter gene under the control of the promoter of interest is transfected into cells,
20 either transiently or stably. Receptor activation leads to a change in enzyme levels via transcriptional and translational events. The amount of enzyme present can be measured via its enzymatic action on a substrate.

25 Host Cell

The host cell for the foregoing screen may be any cell capable of expressing the protein or cDNA library of proteins to be screened. Some suitable host cells have been found to be yeast cells, *Saccharomyces Cerevisiae*, and *E. Coli*.

30

This invention will be better understood from the Experimental Details which follow. However, one skilled in the art will readily appreciate that the specific methods and results discussed are merely illustrative of the invention as described
35 more fully in the claims which follow thereafter.

-40-

EXPERIMENTAL DETAILS

Example 1

We have shown that Dex-Mtx can dimerize a LexA-DHFR and a B42-rGR protein chimera in vivo (Table I). (Lin, 1999) Dex-Mtx was
5 assayed using both plate and liquid assays at extracellular concentrations of 1-100 μ M. No activation was observed at concentrations \leq 0.1 μ M. 100 μ M is the limit of Dex-Mtx solubility. Control experiments established that *lacZ*
10 transcription is dependent on Dex-Mtx. There are only background levels of *lacZ* transcription when Dex-Mtx is omitted, LexA-DHFR is replaced with LexA, or B42-GR is replaced with B42. Likewise, a 10-fold excess of Mtx competes out Dex-Mtx-dependent
15 *lacZ* transcription. Interestingly, of the 10 protein chimera combinations tested, Dex-Mtx could only activate *lacZ* transcription in the context of the LexA-eDHFR and the B42-(Gly6)-rGR chimeras (Table 1). None of the 9 other protein combinations tested worked. This result is consistent with our
20 view that the Dex-Mtx systems (and other dimerization systems) could be further improved both by biochemical and structural characterization and by variation of the protein chimeras and the reporter.

Table I.

Effect of DEX-Mtx on Dimerization of Different LexA-and
B42-Protein Fusions

5	Strain ^a	LexA Chimera	B42 Chimera	Dex-Mtx Dimerization ^b
	1	LexA-eDHFR ^c	B42-Gly ₆ ^d -rGR2 ^e	Yes
	2	LexA-eDHFR	B42-rGR2	No
	3	LexA-eDHFR	B42-(rGR2) ₃	No
	4	LexA-mDHFR ^f	B42-Gly ₆ -rGR2	No
10	5	LexA-mDHFR	B42-rGR2	No
	6	LexA-mDHFR	B42-(rGR2) ₃	No
	7	LexA-rGR2	B42-eDHFR	No
	8	LexA-rGR2	B42-mDHFR	No
	9	LexA-(rGR2) ₃	B42-eDHFR	No
15	10	LexA-(rGR2) ₃	B42-mDHFR	No

^aS. Cerevisiae strain FY250 containing pMW106 (the lacZ reporter plasmid), pMW103 (encoding the LexA chimera), and pMW012 (encoding the B42 chimera). ^bDex-Mtx-dependent dimerization was determined using

20 standard assays for lacZ transcription. See the text for details.

^cthe E. coli DHFR. ^dIn some constructs a 6 Glycine linker was added between B42 and the rGR. ^eA mutant form of the hormone-binding domain of the glucocorticoid receptor (residues 524-795, Phe⁶²⁰ -Ser, Cys⁶⁵⁶ -Gly) with increased affinity for Dex was used in these studies. ^fthe
25 murine DHFR.

Example 2

Cephalosporin Hydrolysis by the 908R Cephalosporinase in the yeast three-hybrid system

30 The subject invention is exemplified using the components of the yeast three-hybrid system (Licitra, represented in Fig. 2, see also U.S. Patent No. 5,928,868). In this system DEX-FK506 (exemplifying H1-H2) mediates dimerization of the protein fusions LexA-GR (representing reporter V-H1 receptor) and B42-
35 FKBP12 (representing reporter W-H2 receptor) thus activating transcription of a lacZ reporter gene. The chemical handles H1 and H2 and the protein dimerization assay, however, all can be varied.

-42-

In the subject invention, however, the yeast three-hybrid system is altered by inserting a BOND, B, as well as any required spacers X and Y, so as to form a small molecule having the structure H1-X-B-Y-H2. While there is ample precedent for small-molecule mediated protein dimerization, what remains is to show these assays can be used to select for catalysts. Cephalosporin hydrolysis by a cephalosporinase provides a simple cleavage reaction to demonstrate the selection (Fig. 3). The BOND, B in this example is cephem linkage susceptible to attack by cephalosporinase, such that hydrolysis of the cephalosporinase results in separation of the proteins and deactivation of the transcription of *lacZ*.

The *E. cloacae* 908R cephalosporinase is well characterized both biochemically (Galleni; Galleni; Galleni; Monnaie) and structurally (Lobkovsky) and is simple to manipulate. Several approaches have been developed for modifying cephalosporin antibiotics at the C7' and C3' positions to improve their pharmacokinetic properties and to prepare pro-drugs. (Druckheimer; Albrecht; Vrudhula; Meyer)

Cephalosporin hydrolysis by the cephalosporinase can disrupt protein dimerization and hence be used to discriminate between cells containing active and inactive enzyme. Specifically, (1) (C.)DEX-CEPHEM-(C3')FK506 is synthesized; (2) DEX-CEPHEM-FK506 is shown to dimerize LexA-GR and B42-FKBP12 and both DEX and FK506 is shown to disrupt the dimerization; (3) induction of the wild type cephalosporinase, but not an inactive Ser⁶⁴ variant, is shown to disrupt cephem-mediated protein dimerization; and (4) cells containing active cephalosporinase are identified based on loss of protein dimerization in a mock screen. A screen for loss of *lacZ* transcription is sufficient for the screen.

The retro-synthesis of DEX-CEPHEM-FK506 is shown in Figure 4; it allows H1, H2, and the linker molecules to be varied. The

-43-

allelic chloride intermediate 2 has been synthesized from cephem
1 in 20% yield in four steps. Mild conditions for coupling H2-
SH to the allelic chloride 2 using sodium iodide have been
developed; DEX-SH can be coupled in 82% yield. 908R
5 cephalosporinase variants have been constructed both with and
without nuclear-localization sequences under control of *GAL1* and
MET25 promoters. All of these variants are known to be active
in vivo by using the chromogenic substrate nitrocefin,
(Pluckthun). Several *S. cerevisiae* strains suitable for this
10 model reaction have been constructed. DEX-FK506 is known to
dimerize LexA-rGR and B42-FKBP12 in these strain backgrounds
(yeast three-hybrid system).

All of the components needed for the proof of principle have
15 been prepared. Specifically, we have developed a modular
synthesis of Dex-cephem-Mtx and constructed a *S. cerevisiae*
strain suitable for the proof principle. The retro-synthesis
of Dex-cephem-Dex is shown in Figure 12; it allows H1, H2, and
the linker molecules to be varied to optimize the cephem
20 substrate. We have synthesized the allylic chloride
intermediate 2 from cephem 1 in 20% yield in four steps. We
have developed mild conditions for coupling H2-SH to the allylic
chloride 2 using sodium iodide; Dex-SH can be coupled in 82%
yield. We have constructed strain
25 FY250/pMW106/pMW2rGR2/pMW3FKBP12 and shown that Dex-FK506 can
still mediate dimerization of LexA-rGR and B42-FKBP12 in this
strain. The strain provides an additional marker for the
enzyme, grows well on galactose and raffinose, and replaces all
of the amp^R markers with kan^R or spec^R markers. In addition, we
30 have constructed several constructs for the galactose- or
methionine-regulated overexpression of the cephalosporinase.
Based on hydrolysis of the chromogenic substrate nitrocefin,
(Pluckthun, 1987) we have shown that the cephalosporinase is
active in the FY250 background.

-44-

The basis for catalysis by the cephalosporinase is studied using combinatorial techniques. Understanding the mechanism is important for anticipating future routes to antibiotic resistance and for developing new cephalosporin antibiotics.

5

Dex-cephem-Mtx induces protein dimerization in vivo


Preparation of a Dex-cephem-Mtx (cleavable cephem linker)

10 The cephem substrates were designed such that introduction of the Dex and Mtx ligands would not interfere with cephalosporinase hydrolysis of the cephem core and so that a variety of Dex-cephem-Mtx substrates could be synthesized readily from commercially available materials. (*The chemistry of the b-lactams*; Durckheimer; Albrecht; Meyer; Zlokarnik) We
15 synthesized four potential Dex-cephem-Mtx substrates from a commercial amino- chloro- cephem intermediate. Dexamethasone was coupled to the C7 amino group of the cephem core via aminocarboxylic acids of different lengths, and methotrexate to the C3' chloro group via aminothiols of different lengths. All
20 four compounds were prepared from three components in 3-4 steps in 10-30% overall yield.

The critical issue was whether introduction of the cephem linker would impede either the cell permeability or the dimerization
25 activity of the Dex-Mtx CID. We screened all four Dex-cephem-Mtx compounds using the yeast two-hybrid *lacZ* transcription assay and determined that all four compounds are cell permeable and that two of these compounds are capable of inducing protein dimerization in vivo, as shown in Figure 15. Based on these
30 results, it appears that the length of the linkers between the cephem core and the Dex and Mtx ligands are important; the cephem core must not be too close to the receptor or it will prevent access to the receptor. These results support the general feasibility of preparing CIDs with cleavable linkers and
35 using these compounds in vivo with the catalysis screen.

-45-

The ability of this Dex-cephem-MTX CID to serve as a read-out for catalysis is evaluated using the well-studied enzymatic reaction, cephem hydrolysis by a cephalosporinase. Hydrolysis of the lactam bond results in expulsion of the leaving group at the C3' position, effectively breaking the bond between Dex and Mtx.



Having identified Dex-cephem-Mtx substrates that are efficient dimerizers in the yeast two-hybrid assay, the next step is to demonstrate that the screen can discriminate between active and inactive enzymes. The penicillin-binding protein (PBP) from *Streptomyces R61* provides a good control "inactive" enzyme to compare to the active Q908R cephalosporinase. (Kelly; Ghuyssen) Cephalosporinases are believed to have evolved from PBPs. (Ghuyssen; Knox) Both enzymes have the same three-dimensional fold and follow the same catalytic mechanism involving an acyl-enzyme intermediate. (Kelly, Lobkovsky) PBPs bind to cephems with high affinity, form the acyl-enzyme intermediate rapidly, but hydrolyze the acyl-enzyme intermediate much more slowly than do cephalosporinases. We have introduced both the Q908R cephalosporinase and the R61 PBP into yeast shuttle vectors that place the enzymes under control of either a galactose-inducible or a methionine-repressible promoter.

-46-

Based on plate assays using the chromagenic substrate nitrocefin, (Pluckthun) the Q908R enzyme was expressed in an active form in yeast with either promoter. This assay cannot detect PBP activity.

5

The Dex-cephem-Mtx CID screen distinguish between the cephalosporinase and the PBP. Yeast strains containing the cephalosporinase hydrolyze the cephem linkage rapidly, disrupting *lacZ* transcription. The PBP, on the other hand, hydrolyze the cephem linkage too slowly to change the levels of *lacZ* transcription significantly.

10

Can the CID screen detect catalytic activity?

Strong support for the feasibility of using CIDs with cleavable linkers to detect catalytic activity is provided by *in vivo* selections for protease activity based on cleavage of internal protease sites engineered in a variety of proteins, including Gal4. With an active Dex-cephem-Mtx CID in hand, our next step is to find conditions where the CID screen gives an enzyme-dependent signal. We envision two scenarios which should result in an enzyme-dependent signal: (1) overexpression of the enzyme relative to the LexA- and B42-reporter proteins and (2) expression of the enzyme prior to expression of the LexA- and B42-reporter proteins. The Brent Y2H vectors currently employed in the lab will have to be modified to allow for control over the levels and timing of LexA- and B42-expression. As supplied, the Brent vectors have the LexA fusion protein under control of the strong, constitutive alcohol dehydrogenase promoter (P_{ADH}) and the B42 fusion protein under control of the strong galactose-inducible promoter (P_{GAL}). Both vectors contain the high-copy yeast 2 μ origin of replication. We plan simply to place the LexA fusion protein under control of a galactose-inducible promoter, just like B42. The GAL promoter is the most tightly regulated promoter available in yeast and is induced by galactose and repressed by glucose. It can be fully repressed,

20

25

30

35

-47-

and it can direct expression of a range of intermediate protein concentrations by varying the relative percentages of glucose and galactose in the growth media. Thus, with both LexA and B42 under control of Gal promoters, these reporter proteins can be
5 turned off and then on or expressed at intermediate concentrations in concert. If this approach does not work, there are many other ways to tune the sensitivity of the system. The expression of the enzyme, LexA, and B42 can all be controlled using other inducible or constitutive promoters or
10 by integrating LexA and B42 into the chromosome. The *lacZ* reporter gene can be replaced with other chromagenic reporters or selectable markers. Alternatively, the sensitivity of the system can be tuned by varying the substrate:product ratio by adding both Dex-cephem-Mtx (substrate) and Dex and Mtx
15 ("product") to the growth media.

Once conditions were found where we can detect enzyme-dependent cleavage of the cephem linker, we carried out a mock screen as a proof-of-principle experiment. Specifically, plasmids
20 encoding the cephalosporinase and the PBP in a ratio of 1:99 will be introduced into a yeast strain carrying the appropriate protein chimera and reporter genes. Cells harboring the cephalosporinase should be white, while those containing the PBP should be blue. Plasmids from these colonies will be isolated
25 and sequenced to confirm the identity of the expressed enzyme.

Level of catalytic activity detected using the CID screen

While these experiments will show that the CID screen can detect catalytic activity, they will not show that the screen can be
30 used to amplify enzymes with low levels of catalytic activity. Thus, our next step is to use cephalosporinase mutants with a range of catalytic efficiencies to quantify and then optimize the sensitivity of the system. Many β -lactamase mutants, either found in clinical settings or constructed by site-directed
35 mutagenesis, have been fully characterized kinetically. Known

mutants of the Q908R cephalase, the *E. cloacae* P99 cephalase (99% identical), and the *E. coli* K12 AmpC β -lactamase (71% homologous) are available spanning a wide range of k_{cat} , K_m , and k_{cat}/K_m values (Table II). To accurately gauge the relative activities of the mutants in the CID and amp^R screens, we will determine kinetic rate constants for the corresponding Q908R cephalase variants with the Dex-cephem-Mtx and ampicillin substrates and nitrocefin as a control. The Q908R cephalase variants will be constructed in the *E. coli* expression vector by site-directed mutagenesis, using a PCR-based method. These proteins will then be purified by nickel-affinity chromatography, and rate constants will be determined by UV spectroscopy, monitoring the disappearance of absorbance due to the β -lactam bond.

After determining the activity of the mutants with Dex-cephem-Mtx and ampicillin *in vitro*, these same mutants are tested in the CID and amp^R screens. In addition to plate and more quantitative liquid *lacZ* assays, the mutants will be evaluated using a *ura3* reporter gene. *Ura3*, which encodes orotidine-5'-phosphate decarboxylase and is required for uracil biosynthesis, is used routinely as a selectable marker in yeast. Since large numbers of protein variants need to be screened for the evolution experiments, it will be important to move from a screen to a growth selection. *Ura3* has the advantage that it can be used both for positive and negative selections-positive for growth in the absence of uracil and negative for conversion of 5-fluoroorotic acid (5-FOA) to 5-fluorouracil, a toxic byproduct. Cleavage of the cephem bond and disruption of *ura3* transcription will be selected for based on growth in the presence of 5-FOA. The advantage to the 5-FOA selection is that the timing of addition of both the Dex-cephem-Mtx substrate and 5-FOA can be controlled. Several other reporter genes, however, have been reported. The mutants are evaluated in *E. coli* using nitrocefin screens and amp^R selections. Mutants with higher

-49-

activity (k_{cat}/K_m) will still show an enzyme-dependent signal (failure to hydrolyze X-gal or growth in the presence of 5-FOA/nitrocefin hydrolysis or resistance to ampicillin), but at some point these assays will not be able to detect the less active mutants. In addition to suggesting what range of activities can be detected with these assays, these experiments may bring surprising results. For example, it may be that detection correlates more strongly with k_{cat} than with K_m or k_{cat}/K_m . Assuming a dynamic range of >1000 , we will proceed with the enzyme evolution experiments. Otherwise, we will focus on optimizing the sensitivity of the screen until we reach this level of sensitivity. The optimization experiments will continue along the same lines as the proof-of-principle experiments, varying the levels and timing of both protein expression and addition of the substrate and product, except they will be carried out with mutant cephalosporins at the limit of detection.

Table II. Wild-type and mutant enzymes are shown with their kinetic rate constants with the chromogenic cephalosporin nitrocefin, as well as the percentage of wild-type k_{cat}/K_m as calculated in that experiment.

Enzyme	K_m (μM)	k_{cat} (s^{-1})	k_{cat}/K_m ($M^{-1} s^{-1}$)	% WT
E. cloacae P99 wt	25 ± 1	780 ± 30	3.1×10^7	100
E. cloacae Q908R wt	23 ± 1	780 ± 30	3.4×10^7	100
K12 AmpC wt	500 ± 100	490 ± 90	1.0×10^6	100
P99 286-290 TSFGN	19 ± 0.5	261 ± 7	1.37×10^7	96
P99 286-290 LTSNR	43 ± 2	330 ± 11	7.7×10^6	54
P99 286-290 NNAGY	31 ± 11	53 ± 10	1.7×10^6	12
K12 Y150S	108 ± 21	2.11 ± 0.12	1.9×10^4	~1
K12 Y150E	356 ± 34	0.51 ± 0.03	1.4×10^3	~0.1
Q908R S64C	> 1000	> 18	1.76×10^4	0.05

-50-

Example 3

CIDs can be used to screen cDNA libraries based on biochemical function. This glycosidase example is used to determine the best method for expressing the cDNA clones and to optimize the screening process.

Proof of Principle - β -Galactosidase Activity Assays

Table III explains the components of each strain. Each strain was constructed from the parent yeast strain FY250 and also contains the pMW106 plasmid, which has the LacZ reporter gene that is turned on only in when the LexA DNA binding domain and the B42 activation are brought in tot he vicinity of each other. We use several different strains because we use DHFR from two different species, mDHFR is from murine, while eDHFR is from E.coli. We are asl oable to switch the small moleculebinding domains. For example, the strain containing LexA-eDHFR with B42-rGH2 is a different strain and behaves differently from the strain containing LexA-rGR2 with B42-eDHFR. We also put in short 6 amino acid linkers between the two domains of our protein chimeras and thus these are different strain as well.

Next, we have chosen to screen a yeast cDNA library for proteins with glycosidase activity (Figure 19).

Table III. Identification of stains used. (Key: eDHFR=E.coli Dihydrofolate Reductase; rGR2=stereoid binding domain of rat Glucocorticoid Receptor (aa 524-795) with point mutations; (rGR2)3=trimer of rGR2; mDHFR=murine Dihydrofolate Reductase; gly6=6 amino acid linker containing 6 glycines; (GSG)2=6 amino acid linker containing glycine-serine-glycine-glycine-serine-glycine.)

Strain	LexA	B42
V375Y	eDHFR	gly6rGR2
V493Y	eDHFR	rGR2
V496Y	mDHFR	gly6rGR2
V495Y	mDHFR	rGR2
V505Y	rGR2	eDHFR
V507Y	rGR2	mDHFR
V501Y	(GSG)2eDHFR	(GSG)rGR2
V504Y	(GSG)2mDHFR	(GSG)rGR2
V494Y	eDHFR	(GSG)rGR2
V497Y	mDHFR	(GSG)rGR2
V510Y	(GSG)2rGR2	(GSG)2eDHFR
V512Y	(GSG)2rGR2	(GSG)2mDHFR
V498Y	(GSG)2eDHFR	rGR2
V502Y	(GSG)2mDHFR	rGR2
V499Y	(GSG)2eDHFR	gly6rGR2
V503Y	(GSG)2mDHFR	gly6rGR2
V509Y	rGR2	(GSG)2eDHFR
V511Y	rGR2	(GSG)2mDHFR
V506Y	(GSG)2rGR2	eDHFR
V508Y	(GSG)2rGR2	mDHFR
V513Y	eDHFR	(rGR2)3
V514Y	mDHFR	(rGR2)3
V517Y	(rGR2)3	eDHFR
V518Y	(rGR2)3	mDHFR
V515Y	(GSG)2eDHFR	(rGR2)3
V516Y	(GSG)2mDHFR	(rGR2)3

Strain	LexA	B42	
V134Y	Sec16p	Sec6p	positive control
V133Y	Sec13	Sec6p	positive control
V381Y	blank	blank	negative control
V379Y	eDHFR	blank	negative control
V560Y	blank	(GSG)2rGR2	negative control

-52-

 β -Galactosidase Activity Assay Results


The results in Table IV are averages of two separate trials. Each strain was examined with small molecules and without small molecules. The absolute activity is given as the β -galactosidase activity with small molecule subtracted from the β -galactosidase activity without small molecule. The average β -galactosidase activity for a strain without small molecule (i.e. the negative control) was about 100 β -galactosidase units. V133Y is a positive control and shows β -galactosidase activity regardless of the presence of small molecule. The β -galactosidase activity of strain V494Y using varying concentrations of D8M is shown in Figure 18.

Table IV - β -galactosidase Activity Assays


15

B-gal activity			
Strains	1 μ M DM1	1 μ M D8M	1 μ M D10M
V375Y	4978	5210	9993
V493Y	5753	5555	5812
V496Y	-30	-27	740
V495Y	15	38	513
V505Y	557	2532	1160
V507Y	-7	-6	-14
V501Y	4662	6660	2286
V504Y	12	30	556
V494Y	9976	10568	9398
V497Y	-8	24	308
V510Y	601	3163	2314
V512Y	-1	-4	6
V498Y	4735	5442	2926
V502Y	21	30	497
V499Y	4368	7012	4013
V503Y	-5	45	1132
V509Y	307	2734	2028
V511Y	-113	-129	-60
V506Y	519	3867	2561
V508Y	0	-5	5


Controls	B-gal activity	
V133Y	1912	(Positive Control)
No small molecules	96.9374475	(Negative Control)

Compounds Used

(DM1)




(D8M)




(D10M)

5



(D7CM)



(D8CM)

Glycoconjugates are the most functionally and structurally diverse molecules in nature. [Varki, 1993] Moreover, it is now well established that carbohydrates and protein- and lipid-bound saccharides play essential roles in many important biological processes, including cell structure, protein targeting, and cell-cell interactions. [Varki, 1993] Accordingly, glycosidases with a broad array of substrate specificities are required to breakdown and modify polysaccharides, glycoproteins, and glycolipids.

10 Using CIDs with structurally diverse carbohydrate linkers, we screen a *S. cerevisiae* cDNA library based on glycosidase activity. There are many examples of well-characterized glycosidases identified in other organisms that are yet to be identified in *S. cerevisiae*. α -Amylase [Sogaard, 1993; Vihinen, 15 1990; Qian, 1994; Wiegand, 1995; Fujimoto, 1998; Wilcox, 1984] and xylanase [Wong, 1988; Biely, 1997] are endo-glycosidases that break down polysaccharides involved in energy storage and cell structure, respectively. Glycoproteins are synthesized by modification of a core glycoside. The GlcNAc1@Asn and GlcNAc1@4GlcNAc linkages in Asn-linked carbohydrates are cleaved by peptide-N⁴-(N-acetyl-b-glucosaminyl)asparagine amidase (PNGase F) and endo-b-N-acetylglucosaminidases (Endo H and Endo F1), respectively. [Tarentino, 1990; Tarentino, 1992; 20 Robbins, 1984; Trimble, 1991] Since each of these enzymes are endo-glycosidases, the CID ligands should not interfere with the enzyme-catalyzed reaction. Likewise, by making a small library of carbohydrate linkers, we screen in an undirected fashion.

30 The diversity of naturally occurring carbohydrates requires us to make a library of Dex-Mtx CIDs with different carbohydrate linkers. Recent advances in the synthesis of oligosaccharides, both in the coupling methods [Schmidt, 1986; Toshima, 1993; Boons, 1996] and in the solid-phase synthesis, [Danishefsky, 1993; Seeberger, 1998; Yan, 1994; Liang, 1996] make it possible 35 to synthesize these linkers. We have chosen to use a method

-55-

developed by Kahne and co-workers which uses anomeric sulfoxides as glycosyl donors and synthesizes carbohydrates from the reducing to the non-reducing end.[Yan, 1994; Liang, 1996] This method can be used both in solution and on solid-support, can
5 form both a- and b-glycosidic bonds, and utilizes readily-synthesized intermediates. Several alternative methods, however, are available, including Wong and co-workers' one-pot solution synthesis[Zhang, 1999; Ye, 2000] and the solid-phase glycal strategy reported by Danishefsky and co-
10 workers.[Danishefsky, 1993; Seeberger, 1998]

We screen a yeast cDNA library based on glycosidase activity using Dex-Mtx CIDs with cleavable glycosidic linkers (Fig. 12). Concurrently, we identify glycosidases from a *S. cerevisiae* cDNA
15 library by screening for cleavage of CIDs with glycosidic linkages. The Dex-Mtx yeast two-hybrid assay is used as the screen by replacing Dex-Mtx with Dex-oligosaccharide-Mtx. First, we carry out a control where we screen for a known glycosidase, chitinase, using a defined substrate. Second, we
20 screen for unknown glycosidases by using a small library of substrates with different glycosidic bonds.

Screen of a *S. cerevisiae* cDNA Library Based on Glycosidase Activity

25 Using Dex-Mtx CIDs with cleavable oligosaccharide linkers, we screen a *S. cerevisiae* cDNA library based on glycosidase activity. As a control, we screen for a known *S. cerevisiae* glycosidase, chitinase. Then, we synthesize a small library of Dex-carbohydrate-Mtx substrates and screen the *S. cerevisiae* cDNA
30 library to identify glycosidases from the >3000 ORFs of unknown function in *S. cerevisiae*.

Introduction of a *S. cerevisiae* cDNA library into the CID selection strain

35 The first step of both the chitinase control and the random

-56-

oligosaccharide library is to introduce a *S. cerevisiae* cDNA library into the CID selection strain. We use a cDNA library reported by Fields and co-workers.[Martzen, 1999] In this library, each cDNA clone is expressed as a GST-fusion protein under control of a copper-inducible promoter on a shuttle vector with a *leu2* marker.[Martzen, 1999; J. R. Hudson, 1997] Transformation efficiencies in yeast are ca. 10^6 - 10^7 using the lithium acetate method, so there is ample redundancy to screen all 6,000 ORFs in *S. cerevisiae*. Active clones can be identified by sequencing the plasmid. For the chitinase control experiment, we make a library with a subset of cDNA clones to test different approaches for expressing the cDNA clones.

Can the *S. cerevisiae* chitinase be identified using the CID selection?

We begin by screening a *S. cerevisiae* cDNA library for a known glycosidase, chitinase. Chitinase hydrolyzes chitin, polymers of β -1,4-linked *N*-acetylglucosamine (GlcNAc) that play a structural role in the cell.[Muzzarelli, 1977] Chitinases from several organisms, including *S. cerevisiae*, have been cloned and characterized.[Correat, 1982; Kuranda, 1987; Kuranda, 1991] It is known that this enzyme can hydrolyze oligomers of β -1,4-GlcNAc ranging from trimers to heterogeneous polymers, suggesting that CIDs such as Dex-(GlcNAc)_n-Mtx should be efficient substrates for this enzyme. Several efficient syntheses of β -1,4-linked GlcNAc have been published.[Banoub, 1992]

The retro-synthetic analysis of our Dex-(GlcNAc)_n-Mtx CID substrate is shown in Figure 20.

The growing carbohydrate chain is linked to the solid support via the Glu portion of Mtx. The glycosidic linkages are formed essentially as reported by Kahne and co-workers using sulfoxide glycosyl donors.[Yan, 1994; Liang, 1996] The final carbohydrate

is introduced as a Dex derivative, and the Mtx synthesis is completed prior to cleavage from the solid support. This synthesis allows the oligosaccharide linker to be varied and both the Dex and the Mtx ligand to be introduced before cleavage from solid support. Alternatively, the synthesis can be carried out in solution, [Kahne, 1989] or other methods for carbohydrate synthesis can be employed. [Zhang, 1999; Ye, 2000; Danishefsky, 1993; Seeberger, 1998] We start with a GlcNAc tetramer as trimers have been shown to be the shortest efficient substrates for chitinases. [Watanabe, 1993]

Initially, *lacZ* plate assays are used to verify that the Dex-(GlcNAc)_n-Mtx substrates are efficient dimerizers in the yeast three-hybrid assay. The results with Dex-cephem-Mtx support the feasibility of incorporating structurally diverse linkers into the CIDs. If the initial chitinase substrates, however, are not efficient dimerizers, the linkers between the CID ligands and the GlcNAc oligomer can be varied, or alternate dimerization assays can be tested. Since large numbers of cDNA clones need to be screened, the transcriptional read-out of the yeast three-hybrid assay may be changed from a screen to a growth selection. Specifically, *ura3*, which encodes orotidine-5'-phosphate decarboxylase and is required for uracil biosynthesis, replaced *lacZ* as the reporter gene. [Boeke, 1984] *Ura3* has the advantage that it can be used both for positive and negative selections—positive for growth in the absence of uracil and negative for conversion of 5-fluoroorotic acid (5-FOA) to 5-fluorouracil, a toxic byproduct. Cleavage of the glycosidic bond and disruption of *ura3* transcription is selected for based on growth in the presence of 5-FOA. The advantage to the 5-FOA selection is that the timing of addition of both the Dex-(GlcNAc)_n-Mtx substrate and 5-FOA can be controlled. Several other reporter genes, however, can be used.

One problem that has the potential of occurring is that the Dex-(GlcNAc)_n-Mtx substrate becomes unstable either because of its

-58-

intrinsic half-life in water or because it is turned over by cellular glycosidases. However, if the substrate has a short half-life in water, the assay conditions can be modified so that the substrate is added late in the assay after the cells have
5 grown to a high density, the substrate can be continuously replenished, or the pH of the media can be buffered. Turnover by cellular glycosidases can simply be seen as an assay in and of itself. Using traditional genetic approaches, random mutations can be introduced into the *S. cerevisiae* genome or the
10 tagged knock-out strains of Winzeler et al. can be used. [Winzeler, 1999] Cells containing a disruptive mutation in the gene or genes cleaving the Dex-(GlcNAc)_n-Mtx substrate can be selected for by growth in the absence of uracil.

15 The final step is to use the Dex-(GlcNAc)_n-Mtx substrate to pull out chitinase from a *S. cerevisiae* cDNA library. As described above, a 5-FOA growth selection is used to screen the Fields cDNA library. In the absence of chitinase, Dex-(GlcNAc)_n-Mtx induces *ura3* transcription, and 5-FOA is converted to the toxic
20 byproduct 5-fluorouracil. Thus, only cells containing active chitinase, or another enzyme that can cleave the substrate, survive. The cDNA clone is readily identified by isolating the plasmid, sequencing the N-terminus of the clone, and comparing this sequence to that of the *S. cerevisiae* genome. The
25 advantage of using a known enzyme is that the enzyme can be tested independently or used to spike the cDNA library. The enzyme can be purified, and the Dex-(GlcNAc)_n-Mtx substrate can be tested *in vitro*. We can vary the format of the cDNA library, the Dex-(GlcNAc)_n-Mtx substrate, the screen, or the assay
30 conditions, or even use a different glycosidase as a control.

Can glycosidases be identified from the >3000 unassigned ORFs in *S. cerevisiae* using the CID selection?

The next step is to determine the activity of the >3000 ORFs in
35 *S. cerevisiae* with unknown function. To detect glycosidase

-59-

activity, the screen is run exactly as with the chitinase control except using Dex-oligosaccharide-Mtx substrates with different glycosidic linkages. The glycosidic linkages is based on the types of carbohydrates and glycoconjugates naturally occurring in yeast. Several activities, including amylase, [Sogaard, 1993; Vihinen, 1990 ; Qian, 1994; Wiegand, 1995; Fujimoto, 1998; Wilcox, 1984] xylanase, [Wong, 1988; Biely, 1997; Georis, 1999] and endo-N-acetylglucosamine hydrolysis activity, [Tarentino, 1990; Tarentino, 1992; Robbins, 1984; Trimble, 1991] can be targeted specifically.

Dex-Mtx CIDs with different oligosaccharide linkers are prepared using the same strategy as for the chitinase substrate (above). The sulfoxide glycosyl donor method for carbohydrate synthesis allows a variety of sugar monomers to be introduced. [Kahne, 1989] Moreover, both the regio- and stereo-chemistry can be controlled. [Yan, 1994; Liang, 1996] As with the chitinase control, the 5-FOA growth selection is used to identify enzymes that cleave the various glycosidic linkages. Each glycoside substrate is tested individually. Mixtures of substrates cannot be tested because the uncleaved substrates would continue to activate *ura3* transcription. If the screen does not pick up any enzymes, known glycosidases from other organisms may be used as controls both for the growth selections and to test the Dex-Mtx substrates *in vitro*.

the foregoing permits the characterization of *in vitro* activity and biological function of glycosidases identified using the CID screen. Similarly, cDNA libraries from other organisms can be screened. The Dex-Mtx substrates can be used to evolve glycosidases with unique specificities. In addition, the cDNA screen can be extended to other classes of enzymes, such as proteases.

-60-

Example 4Evolution of a Diels-Alderase

The Diels-Alder reaction is one of the key carbon-carbon bond
5 forming reactions in synthetic organic chemistry (Fig. 7B).
(Oppolzer; Carruthers) Surprisingly, no natural Diels-Alderase
are known, although catalytic antibodies have been generated for
this reaction. (Braisted; Hilvert; Suckling; Gouverneur) Using
the selection strategy outlined below the *B. subtilis* chorismate
10 mutase is evolved into a "Diels-Alderase" that can catalyze the
cycloaddition of 1-carbamyl-1, 3-butadiene and 2-propanoic acid
(Fig. 7B).

Chorismate mutase (CM) catalyzes the Claisen rearrangement of
15 chorismate to prephenate (Fig. 7A). Like the Diels-Alder
reaction, the Claisen rearrangement is a pericyclic reaction
with a six-membered transition state (ts). This similarity--and
inspection of the active site--suggests that the chorismate
mutase active site can accommodate a Diels-Alder transition
20 state. The structures of the *B. subtilis* and *E. coli* enzymes
and of an antibody that catalyzes this reaction in complexes
with a ts analog have been determined to high resolution.
(Chook; Lee; Haynes) Although it is homotrimeric, we use the
chorismate mutase from *B. subtilis* because it has an open active
25 site and is monofunctional, nonallosteric, and easy to
manipulate. (Gray; Gray)

To create proteins with catalytic efficiencies that rival
natural enzymes we mimic the evolution of natural enzymes.
30 First evolve a rudimentary catalyst from an existing protein
scaffold by demanding that catalysis provide the cell with a
selective advantage. Then improve the catalytic efficiency of
the rudimentary catalyst by subjecting it to further
randomization and recombination and increasing the stringency
35 of the selection.

-61-

We begin with the simple substrates shown in Figure 8. The CM structural data allows design the diene and dienophile (1) to utilize the electrostatic environment in the CM active site and (2) to incorporate H1 and H2 without disrupting substrate binding. It may be necessary, however, to incorporate additional functionality to improve substrate binding or to modulate the electrophilicity of the dienophile to prevent reaction with cellular components.

To select for a Diels-Alderase, we first show that the cycloaddition product, but neither substrate, can mediate protein dimerization. A retro-synthesis of the diene and dienophile is shown in Figure 8. Then we evolve a Diels-Alderase from libraries of CM variants using a *LEU2* selection in which the media is supplemented with the substrates H1-diene and H2-dienophile. Only cells containing active enzyme catalyze the covalent coupling of the substrates, induce protein dimerization and *LEU2* transcription, and hence survive on media without leucine. In practice, we (1) isolate a few rudimentary Diels-Alderases by supplementing the media with low concentrations of leucine; (2) confirm the activity of these enzymes *in vitro* using purified protein; (3) improve the catalytic efficiency of these initial catalysts by further randomization and recombination under more stringent *LEU2* selection conditions; and finally (4) characterize both the rudimentary and improved catalysts *in vitro* using purified protein. The evolution of a Diels-Alderase establishes that the selection strategy can be used to create synthetically useful protein catalysts for chemically demanding transformations.

30

BIBLIOGRAPHY

Albrecht, H.; *et al. J. Med. Chem.* **1990**, *33*, 77-86.

Amara, J. *et al.* (1997) *PNAS, USA* **94**, 10618-10623.

Austin DJ, *et al.*, *Chem Biol.* **1994** Nov, *1*(3): 131-6. Review.

Baca, M.; Scanlan, T.; Stephenson, R.; Wells, J. *Proc. Natl Acad. USA* **1997**, *94*, 10063-10068.

Banoub, J. (1992) Synthesis of Oligosaccharides of 2-amino-2-deoxy sugars. *Chem. Rev.* **92**, 1167-1195.

Baum EZ, Beberitz GA, Gluzman Y., "beta-Galactosidase containing a human immunodeficiency virus protease cleavage site is cleaved and inactivated by human immunodeficiency virus protease." *Proc Natl Acad Sci U S A.* 1990 Dec;87(24):10023-7.

Belshaw PJ, *et al.*, *Chem Biol.*, **1996** Sep, *3*(9); 731-8.

Belshaw PJ, *et al.*, *Proc Natl Acad Sci USA* **1996** May 14, *93*(10): 4604-7.

Biely, P.; Vrsanska, M.; Tenkanen, M.; Kluepfel, D. (1997) Endo-b-1,4-xylanase families: differences in catalytic properties. *J. Biotechnol.* **57**, 151-166.

Bolin, J.; Filman, D.; Matthews, D.; Hamlin, R.; Kraut, J. *J. Biol. Chem.* **1982**, *257*, 13663-13672.

Boons, G. (1996) Strategies in oligosaccharide synthesis. *Tetrahedron* **52**, 1095-1121.

Braisted, A.; Schultz, P. *J. Am. Chem. Soc.* **1990**, *112*, 7430-7431.

Brasemann, S.; Graninger, P.; Busslinger, M. (1993), *PNAS, USA* **90**, 1657-1661.

Cadwell, R.; Joyce, G.; Cold Spring Harbor Laboratory Press; New York, 1994.

Carruthers, W. *Cycloaddition Reactions in Organic Synthesis*; Pergamon Press: Oxford, 1990; Vol. 8.

Chakraborti, P.; Garabedian, M.; Yamamoto, K.; SS Simons, J. *J. Biol. Chem.* **1991**, 266, 22075-22078.

Chook, Y.; Gray, J.; Ke, H.; Lipscomb, W. *J. Mol. Biol.* **1994**, 240, 476-500.

Choi J. et al., *Science*, **1996** Jul 12; 273(5272): 239-42.

Clackson, T. et al., (1998) PNAS, USA **95**, 10437-10442.

Coleman, R.; Danishefsky, S. **1989**, 157-161.

Correat, J. U.; Elango, N.; Polacheck, I.; Cabib, E. (1982) Endochitinase, a Mannan-associated Enzyme from *Saccharomyces cerevisiae*. *J. Biol. Chem.* **257**, 1392-1397.

Crabtree, G.; Schreiber, S. *Trends Biochem. Sci.* **1996**, 21, 418-422.

Crameri, A.; Raillard, S.-A.; Bermudez, E.; Stemmer, W. *Nature* **1998**, 391, 288-91.

Danishefsky, S. J.; McClure, K. F.; Randolph, J. T.; Ruggeri, R. B. (1993) A strategy for the solid-phase synthesis of oligosaccharides. *Science* **260**, 1307-1309.

DeGrado, W.; Nilsson, B. *Curr. Opin. Struc. Biol.* **1997**, 7, 455-456, and following articles.

Diver, ST, *Journal of the American Chemical Society*, **1997** Jun 4, V119 N22; 5106-5109.

Duchene, A.; et al., *Synlett* **1994**, 524-526.

- Durckheimer, W.; Adam, F.; Fischer, G.; Kirrstetter, R. *Adv. Drug Res.* **1988**, 17, 61-234.
- Eisenbeis, S.; *et al.* *Proc. Natl. Acad. Sci. USA* **1985**, 82, 1084-1089.
- Fields, S.; Song, O. *Nature* **1989**, 340, 245-246.
- Fujimoto, Z.; *et al.* (1998) Crystal structure of a catalytic-site mutant α -amylase from *Bacillus subtilis* complexed with maltopentaose. *J. Mol. Biol.* **277**, 393-407.
- Galleni, M.; Frere, J. *Biochem. J.* **1988**, 255, 119-122.
- Galleni, M.; Amicosante, G.; Frere, J. *Biochem. J.* **1988**, 255, 123-129.
- Galleni, M.; *et al.* *Biochem. J.* **1988**, 250, 753-760.
- Ghuysen, J. (1991) Serine β -lactamases and penicillin-binding proteins. *Annu. Rev. Microbiol.* **45**, 37-67.
- Gossen, M.; Bujard, H. (1992) PNAS, *USA* **89**, 5547-5551.
- Gossen, M.; Freundlieb, S.; Bender, G.; Muller, G.; Hiller, W.; Bujard, H. (1995), *Science* **268**, 1766-1769.
- Gouverneur, V.; *et al.* *Science* **1993**, 262, 204-208.
- Govindan, M.; Manz, B. *Eur. J. Biochem.* **1980**, 108, 47-53.
- Gray, J.; Golinelli-Pimpaneau, B.; Knowles, J. *Biochemistry* **1991**, 29, 376-383.
- Gray, J.; Eren, D.; Knowles, J. *Biochemistry* **1990**, 29, 8872-8878.
- Gyuris, J.; Golemis, E.; Chertkov, H.; Brent, R. *Cell* **1993**, 75, 791-803.

Haynes, M.; Sutra, E.; Hilvert, D.; Wilson, I. *Science* **1994**, 263, 646-652.

Hawkins CJ, Wang SL, Hay BA. "A cloning method to identify caspases and their regulators in yeast: identification of *Drosophila* IAP1 as an inhibitor of the *Drosophila* caspase DCP-1." *Proc. Natl Acad Sci U S A*. 1999 Mar 16;96(6):2885-90.

Hermes, J.; Blacklow, S.; Knowles, J. *Proc. Natl. Acad. Sci. USA* **1990**, 87, 696-700.

Hilvert, D.; Kaiser, E. *J. Am. Chem. Soc.* **1985**, 107, 5805-5806.

Hilvert, D. *Curr. Opin. Struct. Biol.* **1994**, 4, 612-617.

Hilvert, D.; Hill, K.; Nared, K.; Auditor, M.-T. *J. Am. Chem. Soc.* **1989**, 111, 9261-9262.

Ho SN, et al., *Nature*, **1996** Aug 29; 382(6594): 822-6.

Holsinger LJ, et al., *Proc Natl Acad Sci USA* **1995** Oct 10, 92(21): 9810-4.

Hu, J.; O'Shea, E.; Kim, P.; Sauer, R. *Science* **1990**, 250, 1400-1403.

Hu, J. *Structure* **1995**, 3, 431-433.

Huang, T.; Barclay, B.; Kalman, T.; vonBorstel, R.; Hastings, P. *Gene* **1992**, 121, 167-171.

J. Hudson; Fields, S.; et al. (1997) The complete set of predicted genes from *Saccharomyces cerevisiae* in a readily usable form. *Genome Res.* **7**, 1169-1173.

Hung, DT, *Chemistry & Biology*, **1996** Aug, V3 N8: 623-639.

Imperiali, B.; Roy, R. *J. Am. Chem. Soc.* **1994**, 116, 12083-12084.

Jacobsen, J.; et al. *Science* **1992**, 256, 365-367.

Johnson K.; Allemann, R.; Widmer, H.; Benner, S. *Nature* **1993**, 365, 530-532.

Johnsson, N.; Varshavsky, A. *Proc. Natl. Acad. Sci. USA* **1994**, 91, 10340-10344.

Kahne, D.; Walker, S.; Cheng, Y.; Engen, D. V. (1989) Glycosylation of unreactive substrates. *J. Am. Chem. Soc* **111**, 6881-6882.

Kaiser, E.; Lawrence, D. *Science* **1984**, 226, 505-511.

Kamada S, Kusano H, Fujita H, Ohtsu M, Koya RC, Kuzumaki N, Tsujimoto Y. "A cloning method for caspase substrates that uses the yeast two-hybrid system: cloning of the antiapoptotic gene gelsolin." *Proc Natl Acad Sci U S A*. 1998 Jul 21;95(15):8532-7.

Karimova, G.; Pidoux, J.; Ullmann, A.; Ladant, D. *Proc. Natl. Acad. Sci. USA* **1998**, 95, 5752-5756.

Kast, P.; Asif-Ullah, M.; Jiang, N.; Hilvert, D. *Proc. Natl. Acad. Sci. USA* **1996**, 93, 5043-5048.

Kelly, J.; *et al.* (1986) On the origin of bacterial resistance to penicillin: comparison of a b-lactamase and a penicillin target. *Science* **231**, 1429-1437.

Knowles, J. *Science* **1987**, 236, 1252-1258.

Koltermann, A.; *et al.* *Proc. Natl. Acad. Sci. USA* **1998**, 95, 1421-1426.

Klemm, JD, *Annu Rev Immunol*, **1998**, 16:569-92.

Knox, J.; Moews, P.; Frere, J. (1996) Molecular evolution of bacterial b-lactam resistance. *Chemistry & Biology* **3**, 937-947.

Kralovec, J.; Spencer, G.; Blair, A.; Mammen, M.; Singh, M.; Ghose, T. *J. Med. Chem.* **1989**,

32, 2426-2431.

Kuranda, M. J.; Robbins, P. W. (1987) Cloning and heterologous expression of glycosidase genes from *Saccharomyces cerevisiae*. *Proc. Natl. Acad. Sci. USA* **84**, 2585-2589.

Kuranda, M. J.; Robbins, P. W. (1991) Chitinase is required for cell separation during growth of *Saccharomyces cerevisiae*. *J. Biol. Chem.* **266**, 19758-19767.

Lee, A.; Karplus, P.; Ganem, B.; Clardy, J. *J. Am. Chem. Soc.* **1995**, *117*, 3627-3628.

Leung, D.; Chen, E.; Goeddel, D. *Technique* **1989**, *1*, 11-15.

Liang, R.; Kahne, D.; *et al.* (1996) Parallel synthesis and screening of a solid phase carbohydrate library. *Science* **274**, 1520-1522.

Licitra, E.; Liu, J. *Proc. Natl. Acad. Sci. USA* **1996**, *93*, 12817-12821.

Lin, H., Abida, W., Sauer, R., Cornish, V., *in preparation*, 1999.

Lobkovsky, E.; *et al.* *Proc. Natl. Acad. Sci. USA* **1993**, *90*, 11257-11261.

Manz, B.; Heubner, A.; Kohler, I.; Grill, H.-J.; Pollow, K. *Eur. J. Biochem.* **1983**, *131*, 333-338.

Martzen, M. R.; McCraith, S. M.; Spinelli, S. L.; Torres, F. M.; Fields, S.; Grayhack, E. J.; Phizicky, E. M. (1999) A biochemical genomics approach for identifying genes by the activity of their products. *Science* **286**, 1153-1155.

Meyer, D.; *et al.* *Bioconjugate Chem.* **1995**, *6*, 440-446.

Monnaie, D.; Virden, R.; Frere, J. *FEBS* **1992**, *306*, 108-112.

No, D.; Yao, T.; Evans, R. (1996) PNAS, USA 93, 3346-3351.

Oppolzer, W. In *Comp. Org. Syn.*; B. Trost and I. Fleming, Eds.; Pergamon Press: New York, 1991; Vol. 5; pp 315-399.

Overman, L; Taylor, G.; Petty, C.; Jessup, P. J. Org. Chem. 1978, 43, 2164-2167.

The chemistry of the β -lactams; Page, M., Ed.; Chapman & Hall: Glasgo, 1992.

Pedersen, H.; *et al. Proc. Acad. Sci. USA* 1998, 95, 10523-10528.

Picard, D.; Yamamoto, K. *EMBO J.* 1987, 6, 3333-3338.

Pluckthun, A.; Knowles, J. *J. Biol. Chem.* 1987, 262, 3951-3957.

Posner, B.; Smiley, J.; Lee, I.; Benkovic, S. *Trends Biochem. Sci.* 1994, 19, 145-150.

Pruschy, M.; Spencer, D.; Kapoor, T.; Miyake, H.; Crabtree, G.; Schreiber, S. *Chem. Biol.* 1994, 1, 163-172.

Qian, M.; Haser, R.; Buisson, G.; Duee, E.; Payan, F. (1994) The active center of a mammalian alpha-amylase. Structure of the complex of a pancreatic alpha-amylase with a carbohydrate inhibitor refined to 2.2-Å resolution. *Biochemistry* 33, 6284-94.

Reidhaar-Olson, J.; *et al. Methods Enz.* 1991, 208, 564-586.

Robbins, P.; Trimble, R.; Wirth, D.; Hering, C.; Maley, F.; Maley, G.; Das, R.; Gibson, B.; Royal, N.; Biemann, K. (1984) Primary structure of the Streptomyces enzyme endo-beta-N-acetylglucosaminidase H. *J. Biol. Chem.* 259, 7577-7583.

Rossi, R.; Charlton, C.; Blau, H. *Proc. Natl. Acad. Sci.* 1997, 94, 8405-8410.

Rosen, M.; Schreiber, S. (1992), *Angew. Chem. Int. Ed. Engl.* **31**, 384-400.

Sasso, S.; Gilli, R.; Sari, J.; Rimet, O.; Briand, C. *Biochim. Biophys. Acta* **1994**, 1207, 74-79.

Schmidt, R. (1986) New methods for the synthesis of glycosides and oligosaccharides-Are there alternatives to the Koenigs-Knorr method? *Angew. Chem. Int. Ed. Engl.* **25**, 212-235.

Schreiber, SL, *Bioorg Med Chem* 1998 Aug;6(8): 1127-52.

Schultz, P. *Ang. Chem. Int. Ed. Eng.* **1989**, 28, 1283-1444.

Schultz, P.; Lerner, R. *Science* **1995**, 269, 1835-1842.

Seeberger, P. H.; Danishefsky, S. J. (1998) Solid-phase synthesis of oligosaccharides and glycoconjugates by the glycal assembly method: A five year retrospective. *Acc. Chem. Res* **31**, 685-695.

Shokat, K.; Leumann, C.; Sugawara, R.; Schultz, P. *Science* **1989**, 338, 269-272.

Smith TA, Kohorn BD. "Direct selection for sequences encoding proteases of known specificity." *Proc Natl Acad Sci U S A.* 1991 Jun 15;88(12):5159-62.

Sogaard, M.; Kadziola, A.; Haser, R.; Svensson, B. (1993) Site-directed mutagenesis of His93, Asp180, Glu205, His290, Asp291 at the active site and Trp279 at the raw starch binding site in Barley α -amylase I. *J. Biol. Chem.* **268**, 22480-22484.

Spencer DM, et al., *Curr Biol.* **1996** Jul 1, 6(7): 839-47.

Spencer DM, et al., *Proc Natl Acad Sci USA* **1995** Oct 10, 92(21): 9805-9.

Spencer, D.; Wandless, T.; Schreiber, S.; Crabtree, G. *Science* **1993**, 262, 1019-1024.

Stemmer, W. *Proc. Natl. Acad. Sci. USA* 1994, 91, 10747-10751.

Stemmer, W. *Nature* 1994, 370, 389-391.

Stockwell, BR, *Chem Biol.*, 1998 Jul 5(7): 385-95.

Stockwell, BR, *Curr Biol.*, 1998 Jun 18; 8(13): 761-70.

Suckling, C.; et al. *Biorg. Med. Chem. Lett.* 1992, 2, 49-53.

Tarentino, A.; Quinones, G.; Trumble, A.; Changchien, L.; Duceman, B.; Maley, F. (1990) Molecular cloning and amino acid sequence of peptide-N4-(N-acetyl-beta-D-glucosaminyl)asparagine amidase from *flavobacterium meningosepticum*. *J. Biol. Chem.* 265, 6961-6966.

Tarentino, A.; TH Plummer, J.; et al. (1992) Multiple endoglycosidase (Endo) F activities expressed by *Flavobacterium meningosepticum*. *J. Biol. Chem.* 267, 3868-3872.

Toshima, K.; Tatsuta, K. (1993) Recent progress in O-glycosylation methods and its application to natural products synthesis. *Chem. Rev.* 93, 1503-1531.

Trimble, R.; Tarentino, A. (1991) Identification of distinct endoglycosidase (Endo) activities in *Flavobacterium meningosepticum*: Endo F1, Endo F2, and Endo F3. *J. Biol. Chem.* 266, 1646-1651.

Varki, A. (1993) Biological roles of oligosaccharides: all the theories are correct. *Glycobiology* 3, 97-130.

Vihinen, M.; Mantsala, P.; et al. (1990) Site-directed mutagenesis of a thermostable α -amylase from *Bacillus stearothermophilus*: putative role of three conserved residues. *J. Biochem.* 107, 267-272.

- Vrudhula, V.; Svensson, H.; Senter, P. J. *Med. Chem.* **1995**, 38, 1380-1385.
- Wagner, J.; Lerner, R.; Barbas, C. *Science* **1995**, 270, 1797-1800.
- Wagner, R.; Rhoades, T.; Or, Y.; Lane, B.; Hsieh, G.; Mollison, K.; Luly, J. J. *Med. Chem.* **1998**, 41, 1764-1776.
- Wang, Y.; BW O'Malley, J.; Tsai, S.; O'Malley, B. (1994) PNAS, *USA* **91**, 8180-8184.
- Wells, J.; Vasser, M.; Powers, D. *Gene* **1985**, 34, 315-323.
- Wharton, R.; Patashne, M. *Nature* **1985**, 316, 601-605.
- Wiegand, G.; Epp, O.; Huber, R. (1995) The crystal structure of porcine pancreatic α -amylase in complex with the microbial inhibitor tendamistat. *J. Mol. Biol.* **247**, 99-110.
- Wilcox, E.; Whitaker, J. (1984) Some aspects of the mechanism of complexation of red kidney bean α -amylase inhibitor and α -amylase. *Biochemistry* **23**, 1783-1791.
- Wilks, H.; *et al.* *Science* **1988**, 242, 1541-1544.
- Wong, K.; Tan, L.; Saddler, J. (1988) Multiplicity of β -1,4-zylanase in microorganisms: Functions and applications. *Microbiol. Rev.* **52**, 305-317.
- Yan, L.; Taylor, C. M.; R. Goodnow, J.; Kahne, D. (1994) Glycosylation on the Merrifield resin using anomeric sulfoxides. *J. Amer. Chem. Soc.* **116**, 6953-6954.
- Yang J., *Curr Biol* **1998**, Jan 1, 8(1): 11-8.
- Ye, X.; Wong, C. (2000) Anomeric reactivity-based one-pot oligosaccharide synthesis: A rapid route to oligosaccharide libraries. *J. Org. Chem.* **65**, 2410-2431.

Zhang, J.; Dawes, G.; Stemmer, W. *Proc. Natl. Acad. Sci. USA* **1997**, *94*, 4504-4509.

Zhang, Z.; Ollmann, I. R. (1999) Programmable one-pot oligosaccharide synthesis. *J. Amer. Chem. Soc.* **121**, 134-153.

Zlokarnik, G.; *et al.* (1998) Quantitation of transcription and clonal selection of single living cells with a b-lactamase reporter. *Science* **279**, 84-88

Zoller, M.; Smith, M. *Methods Enz.* **1983**, *200*, 468-500.

-73-

What is claimed is:

1. A compound having the formula:



wherein each of H1 and H2 may be the same or different and capable of binding to a receptor which is the same or different;

wherein each of X and Y may be present or absent and, if present, each may be the same or different spacer moiety;

wherein B is an enzyme-cleavable moiety.

2. The compound of claim 1, wherein each of H1 and H2 is capable of binding to a receptor with a IC_{50} of less than 100 nM.
3. The compound of claim 2, wherein each of H1 and H2 is capable of binding to a receptor with a IC_{50} of less than 10 nM.
4. The compound of claim 3, wherein each of H1 and H2 is capable of binding to a receptor with a IC_{50} of less than 1 nM.
5. The compound of claim 1, wherein B is capable of binding to an enzyme with an IC_{50} of less than 100 mM.
6. The compound of claim 5, wherein B is capable of binding to an enzyme with an IC_{50} of less than 10 mM.
7. The compound of claim 6, wherein B is capable of binding to an enzyme with an IC_{50} of less than 1 mM.

8. The compound of claim 1, wherein B is capable of binding to an enzyme with an IC_{50} of less than 100 μM .
9. The compound of claim 5, wherein B is capable of binding to an enzyme with an IC_{50} of less than 10 μM .
10. The compound of claim 6, wherein B is capable of binding to an enzyme with an IC_{50} of less than 1 μM .
11. The compound of claim 1, wherein H1 and H2 are different.
12. The compound of claim 1, wherein X and Y are different.
13. The compound of claim 1, wherein B is cleavable by an enzyme selected from the group of enzymes consisting of transferases, hydrolases, lyases, isomerases, and ligases.
14. The compound of claim 13, wherein the transferase is selected from the group consisting of, a carbon transferase, an aldehyde or ketone transferase, an acyl transferase, a glycosyl transferase, an alkyl or aryl transferase, a N-containing group transferase, a P-containing group transferase, an S-containing group transferase, an O-containing group transferase, and a Se-containing group transferase.
15. The compound of claim 13, wherein the hydrolase is selected from the group consisting of an ester hydrolase, a glycosidic hydrolase, an ether hydrolase, a peptide hydrolase, a C-N (non-peptide) hydrolase, an acid anhydride hydrolase, a C-C hydrolase, a P-N hydrolase, an S-N hydrolase, a C-P hydrolase, C-O hydrolase (non-ester, non-ether), and an S-S hydrolase.

16. The compound of claim 13, wherein the lyase is selected from the group consisting of a C-C lyase, a C-O lyase, a C-N lyase, a C-S lyase, and a P-O lyase.
17. The compound of claim 13, wherein the isomerase is selected from the group consisting of racemases, epimerases, cis-trans isomerases, intra-oxidoreductases, intra-transferases (mutases), and intramolecular lyases.
18. The compound of claim 13, wherein the ligase is selected from the group consisting of a C-O ligase, a C-S ligase, a C-N ligase, a C-C ligase, and a P-O ligase.
19. The compound of claim 1, wherein B is an enzyme cleavable moiety selected from the group consisting of phosphodiester, glycoside, amide, ester, diester, and aldol product moiety.
20. The compound of claim 19, wherein B represents an amide moiety.
21. The compound of claim 20, wherein B represents a cephem moiety.
22. The compound of claim 1, wherein H1 or H2 is derived from a compound selected from the group consisting of steroids, hormones, nuclear receptor ligands, cofactors, antibiotics, sugars, enzyme inhibitors, and drugs.
23. The compound of claim 22, wherein H1 or H2 represents a compound selected from the group consisting of dexamethasone, 3,5,3'-triiodothyronine, trans-retinoic acid, biotin, coumermycin, tetracycline, lactose,


-76-

methotrexate, FK506, and FK506 analogs.


24. The compound of claim 23, wherein H1 or H2 is derived from the compound of Figure 5A.
25. The compound of claim 23, wherein H1 or H2 is derived from the compound of Figure 5B.
26. The compound of claim 23, wherein H1 or H2 is derived from the compound of Figure 5C.

-77-

27. The compound of claim 1, formed by reacting a first compound having the formula:



with a second compound having the formula:




wherein B' and B'' are moieties that react to form B in the presence of an enzyme.

28. The compound of claim 27, wherein the enzyme is selected from the group of enzymes consisting of transferases, lyases, isomerases, and ligases.
29. The compound of claim 28, wherein the transferase is selected from the group consisting of, a carbon transferase, an aldehyde or ketone transferase, an acyl transferase, a glycosyl transferase, an alkyl or aryl transferase, a N-containing group transferase, a P-containing group transferase, an S-containing group transferase, an O-containing group transferase, and a Se-containing group transferase.
30. The compound of claim 28, wherein the lyase is selected from the group consisting of a C-C lyase, a C-O lyase, a C-N lyase, a C-S lyase, and a P-O lyase.
31. The compound of claim 28, wherein the isomerase is selected from the group consisting of racemases, epimerases, cis-trans isomerases, intra-oxidoreductases, intra-transferases (mutases), and intramolecular lyases.
32. The compound of claim 28, wherein the ligase is selected from the group consisting of a C-O ligase, a C-S ligase,

-78-

a C-N ligase, a C-C ligase, and a P-O ligase.

33. A compound having the formula:



wherein H1 is capable of binding to a receptor;

wherein X is a spacer moiety which may be present or absent; and


wherein B' is a moiety capable of binding to an enzyme.

34. The compound of claim 33, wherein H1 is capable of binding to a receptor with a IC_{50} of less than 100 nM.
35. The compound of claim 34, wherein H1 is capable of binding to a receptor with a IC_{50} of less than 10 nM.
36. The compound of claim 35, wherein H1 is capable of binding to a receptor with a IC_{50} of less than 1 nM.
37. The compound of claim 33, wherein B' is capable of binding to an enzyme with an IC_{50} of less than 100 mM.
38. The compound of claim 37, wherein B' is capable of binding to an enzyme with an IC_{50} of less than 50 mM.
39. The compound of claim 38, wherein B' is capable of binding to an enzyme with an IC_{50} of less than 1 mM.
40. The compound of claim 39, wherein B' is capable of binding to an enzyme with an IC_{50} of less than 100 μ M.
41. The compound of claim 40, wherein B' is capable of binding

-79-

to an enzyme with an IC_{50} of less than 10 μM .

42. The compound of claim 41, wherein B' is capable of binding to an enzyme with an IC_{50} of less than 1 μM .
43. The compound of claim 33, further capable of reacting with a moiety that has the formula:



wherein H_2 is capable of binding to a receptor;

wherein Y is a spacer moiety which may be present or absent; and

wherein B'' is a moiety that reacts with B' in the presence of the enzyme.

44. A complex comprising the compound of claim 1 complexed to an enzyme.
45. The complex of claim 44, wherein the compound is capable of binding to the enzyme with an IC_{50} of less than 100 mM.
46. The complex of claim 44, wherein the compound is capable of binding to the enzyme with an IC_{50} of less than 10 mM.
47. The complex of claim 44, wherein the compound is capable of binding to the enzyme with an IC_{50} of less than 1 mM.
48. The complex of claim 44, wherein the compound is capable of binding to the enzyme with an IC_{50} of less than 100 μM .
49. The complex of claim 44, wherein the compound is capable

-80-

of binding to the enzyme with an IC_{50} of less than 10 μM .

50. The complex of claim 44, wherein the compound is capable of binding to the enzyme with an IC_{50} of less than 1 μM .
51. A complex comprising the compound of claim 33 complexed to an enzyme.
52. The complex of claim 51, wherein the compound is capable of binding to the enzyme with an IC_{50} of less than 100 nM .
53. The complex of claim 51, wherein the compound is capable of binding to the enzyme with an IC_{50} of less than 10 nM .
54. The complex of claim 51, wherein the compound is capable of binding to the enzyme with an IC_{50} of less than 1 nM .
55. The complex of claim 51, wherein the compound is capable of binding to the enzyme with an IC_{50} of less than 100 μM .
56. The complex of claim 51, wherein the compound is capable of binding to the enzyme with an IC_{50} of less than 10 μM .
57. The complex of claim 51, wherein the compound is capable of binding to the enzyme with an IC_{50} of less than 1 μM .
58. A composition comprising the compound of claim 1, and the compound of claim 33.
59. The composition of claim 58, further comprising an enzyme.
60. A composition comprising the complex of claim 44.
61. A composition comprising the complex of claim 51.

-81-

62. A method of screening proteins for the ability to catalyze bond cleavage, comprising the steps of:

a) providing a cell that expresses a pair of fusion proteins which upon dimerization change a cellular readout;

b) providing a compound which dimerizes the pair of fusion proteins, said compound comprising two portions coupled by a bond that is cleavable by the protein to be screened; and

c) screening for the cellular readout, wherein a change in the cellular readout indicates catalysis of bond cleavage by the protein to be screened.

63. The method claim 62, wherein the cellular readout is reconstitution of enzymatic activity.

64. The method of claim 62, further comprising providing a cell that contains a gene which is activated by the dimerized pair of fusion proteins.

65. The method of claim 64, wherein the cellular readout is gene transcription, such that a decrease of gene transcripton indicates catalysis of bond cleavage by the protein to be screened.

66. The method of claim 65, wherein the gene transcribed is *lacZ*, *leu2*, *ura3*, *his3*, or *trp*.

67. The method of claim 62, wherein the compound which dimerizes the pair of fusion proteins is the compound of claim 1.

-82-

68. The method of claim 62, wherein the compound which dimerizes the pair of fusion proteins is the compound of claim 43.
69. A method of screening proteins for the ability to catalyze bond formation, comprising the steps of:
- a) providing a cell that expresses a pair of fusion proteins which upon dimerization activate a cellular readout:
 - b) providing a first compound and a second compound, each being capable of binding to one of the pair of fusion proteins, said first and second compound comprising a portion through which the first and second compounds are coupled by the action of the bond forming protein to be screened; and
 - c) screening for the cellular readout, wherein a change in the cellular readout indicates catalysis of bond formation by the protein to be screened.
70. The method of claim 69, wherein the cellular readout is enzyme activity.
71. The method of claim 69, further comprising providing a cell that contains a gene which is activated by the dimerized pair of fusion proteins.
72. The method of claim 69, wherein the cellular readout is gene transcription, such that an increase in gene transcription indicates catalysis of bond formation by the protein to be screened.
73. The method of claim 69, wherein either the first or the second compound is the compound of claim 23.

-83-

74. The method of claim 62 or 69, wherein the cell is selected from the group consisting of yeast, bacteria or mammalian.
75. The method of claim 62 or 69, wherein the cell is selected from the group consisting of *S. cerevisiae*, and *E. coli*.
76. The method of claim 62 or 69, wherein the pair of fusion proteins is the hormone binding domain of the rat glucocorticoid receptor (rGR2) fused to LexA, and FKBP12 fused to the B42 transcriptional activation domain.
77. The method of claim 62 or 69, wherein the pair of fusion proteins is dihydrofolate reductase (DHFR) fused to LexA, and FKBP12 fused to the B42 transcriptional activation domain.
78. The method of claim 62 or 69, wherein the pair of fusion proteins is dihydrofolate reductase (DHFR) fused to LexA, and the rat glucocorticoid receptor (rGR2) fused to the B42 transcriptional activation domain.
79. The method of claim 62 or 69, wherein the pair of fusion proteins is the rat glucocorticoid receptor (rGR2) fused to LexA, and the hormone binding domain of dihydrofolate reductase (DHFR) fused to the B42 transcriptional activation domain.
80. The method of claim 62 or 69, wherein the pair of fusion proteins is dihydrofolate reductase (DHFR) fused to LexA, and the hormone binding domain of the rat glucocorticoid receptor (rGR2) fused through a 6-Glycine linker to the B42 transcriptional activation domain.
81. The method of claim 62 or 69, wherein the protein to be screened is an enzyme selected from the group of enzyme

-84-

classes consisting of transferases, hydrolases, lyases, isomerases and ligases.

82. The method of claim 62 or 69, wherein the screening is performed by Fluorescence Activated Cell Sorting (FACS), or gene transcription markers selected from the group consisting of Green Fluorescence Protein, LacZ- β -galactosidases, luciferase, antibiotic resistant β -lactamases, and yeast markers.

83. A method of screening a compound for the ability to inhibit an enzyme comprising:

screening for activity of the enzyme by the method of claim 62 or 69, and obtaining cells which express an active enzyme, and

contacting the cells with the drug to be screened, wherein a change in the transcription of the reporter gene within the cell after contact with the drug indicates inhibition of the enzyme by the drug.

84. A drug for the inhibition of an enzyme selected by the method of claim 83.

85. A method of evolving a protein with a new catalytic activity comprising screening by the method of claim 62 or 69 proteins derived from a library of proteins which are mutants of a known protein.

86. A protein with new catalytic activity evolved by the method of claim 85.

87. A method of evolving an enzyme with a new substrate

-85-

specificity comprising screening by the method of claim 62 or 69 enzymes derived from a library of enzymes which are mutants of an enzyme with known substrate specificity.

88. An engineered enzyme having new substrate specificity evolved by the method of claim 87.

89. A method for evolving an enzyme that functions with a cofactor which is different from the cofactor the natural coenzyme uses, comprising:

evolving mutants of the natural coenzyme; and

screening the mutants of the natural coenzyme by the method of claim 62 or 69 in the presence of a cofactor different from the cofactor of the natural enzyme.

90. An engineered enzyme that functions with a cofactor which is different from cofactors the enzymes naturally uses evolved by the method of claim 89.

-86-

91. A compound having the formula:




wherein H1 is methorexate or an analog thereof;
wherein H2 is capable of binding to a receptor, and
wherein Y is a moiety providing a covalent linkage between H1 and H2, which may be present or absent, and when absent, H1 is covalently linked to H2.


92. The compound of claim 91, wherein H2 is Dex or an analog thereof.

93. The compound of claim 91, wherein H1 is Mtx and H2 is Dex or an analog thereof.


94. The compound of claim 91, having the formula:



95. The compound of claim 91, having the formula:




96. The compound of claim 95, having the formula:




-87-

97. The compound of claim 91, wherein H2 is capable of binding to a receptor with a IC50 of less than 100 mM.
98. The compound of claim 91, wherein H2 is capable of binding to a receptor with a IC50 of less than 10 mM.
99. The compound of claim 91, wherein H2 is capable of binding to a receptor with a IC50 of less than 1 mM.
100. The compound of claim 91, wherein H2 is capable of binding to a receptor with a IC50 of less than 100 μ M.
101. The compound of claim 91, wherein H2 is capable of binding to a receptor with a IC50 of less than 10 μ M.
102. The compound of claim 91, wherein H2 is capable of binding to a receptor with a IC50 of less than 1 μ M.
103. The compound of claim 91, wherein H2 is capable of binding to a receptor with a IC50 of less than 100 nM.
104. The compound of claim 91, wherein H2 is capable of binding to a receptor with a IC50 of less than 10 nM.
105. The compound of claim 91, wherein H2 is capable of binding to a receptor with a IC50 of less than 1 nM.
106. The compound of claim 95 having the formula:




-88-


107. The compound of claim 95 having the formula:




108. The compound of claim 95 having the formula:



109. The compound of claim 95 having the formula:



110. The compound of claim 95, having the formula:



-89-

111. A complex between the compound of claim 91 and a fusion protein which comprises a binding domain capable of binding to methotrexate, wherein H1 of the compound binds to the binding domain of the fusion protein.
112. The complex of claim 111, wherein the binding domain is that of the dihydrofolate reductase (DHFR).
113. The complex of claim 111, wherein H1 is capable of binding to the binding domain of the fusion protein with an IC50 of less than 100 nM.
114. The complex of claim 111, wherein H1 is capable of binding to the binding domain of the fusion protein with an IC50 of less than 10 nM.
115. The complex of claim 111, wherein H1 is capable of binding to the binding domain of the fusion protein with an IC50 of less than 1 nM.
116. The complex of claim 111, wherein H1 is capable of binding to the binding domain of the fusion protein with an IC50 of less than 100 pM.
117. The complex of claim 111, wherein H1 is capable of binding to the binding domain of the fusion protein with an IC50 of less than 10 pM.
118. The complex of claim 111, wherein H1 is capable of binding to the binding domain of the fusion protein with an IC50 of less than 1 pM.
119. The complex of claim 111, wherein the fusion protein is DHFR-(DNA-binding domain).

120. The complex of claim 111, wherein the fusion protein is DHFR-LexA.
121. The complex of claim 111, wherein the fusion protein is DHFR-(transcription activation domain).
122. The complex of claim 111, wherein the fusion protein is DHFR-B42.
123. A complex between the compound of any one of claims of claims 106-110, and the fusion protein DHFR-LexA.
124. The complex between the compound of any one of claims of claims 106-110, and the fusion protein DHFR-B42.
125. A cell comprising the complex of claim 111.
126. The cell of claim 125, where the cell is selected from the group consisting of yeast, bacteria or mammalian.
127. The cell of claim 125, where the cell is selected from the group consisting of *S. cerevisiae*, and *E. coli*.
128. A method of dimerizing two fusion proteins inside a cell using the compound of claim 91, comprising the steps of a) providing a cell that expresses a first fusion protein which comprises a binding domain that binds to H1 and second fusion protein which comprises a binding domain that binds to H2, and b) contacting the compound of claim 91 with the cell so as to dimerize the two fusion proteins.
129. The method of claim 128, wherein the first fusion protein or the second fusion protein is DHFR-(DNA-binding domain).

-91-

130. The method of claim 128, wherein the first fusion protein or the second fusion protein is DHFR-LexA.

131. The method of claim 128, wherein the first fusion protein or the second fusion protein is DHFR-(transcription activation domain).

132. The method of claim 128, wherein the first fusion protein or the second fusion protein is DHFR-B42.

133. A method for identifying a molecule that binds a known target in a cell from a pool of candidate molecules, comprising:

(a) covalently bonding each molecule in the pool of candidate molecules to a methotrexate moiety or an analog of methotrexate to form a screening molecule;

(b) introducing the screening molecule into a cell which expresses a first fusion protein comprising a binding domain capable of binding methotrexate, a second fusion protein comprising the known target, and a reporter gene wherein expression of the reporter gene is conditioned on the proximity of the first fusion protein to the second fusion protein;

(c) permitting the screening molecule to bind to the first fusion protein and to the second fusion protein so as to activate the expression of the reporter gene;

(d) selecting which cell expresses the reporter gene; and

(e) identifying the small molecule that binds the known target.

134. The method of claim 133, wherein the cell is selected from the group consisting of insect cells, yeast cells, mammalian cell, and their lysates.

135. The method of claim 133, wherein the first or the second fusion protein comprises a transcription module selected from the group consisting of a DNA binding protein and a transcriptional activator.
136. The method of claim 133, wherein the molecule is obtained from a combinatorial library.
137. The method of claim 133, wherein the steps (b)-(e) of the method are iteratively repeated in the presence of a preparation of random small molecules for competitive binding with the hybrid ligand so as to identify a molecule capable of competitively binding the known target.
138. A method for identifying a protein target to which a molecule is capable of binding, comprising:
- (a) providing a screening molecule comprising a methotrexate moiety or an analog of methotrexate covalently bonded to a ligand which has a specificity for an unknown protein target;
 - (b) introducing the screening molecule into a cell which expresses a first fusion protein comprising a binding domain capable of binding methotrexate, a second fusion protein comprising the unknown protein target, and a reporter gene wherein expression of the reporter gene is conditioned on the proximity of the first fusion protein to the second fusion protein;
 - (c) permitting the screening molecule to bind to the first fusion protein and to the second fusion protein so as to activate the expression of the reporter gene;

-93-

- (d) selecting which cell expresses the reporter gene; and
- (e) identifying the unknown protein target.

139. The method of claim 138, wherein the unknown protein target is encoded by a DNA from the group consisting of genomicDNA, cDNA and syntheticDNA.

140. The method of claim 138, wherein the ligand has a known biological function.

1/23

FIGURE 1A





FIGURE 1B



2/23




FIGURE 3

3/23





FIGURE 4



5/23

FIGURE 5A




FIGURE 5B




FIGURE 5C





FIGURE 6



7/23

FIGURE 7A








FIGURE 7B




8/23



9/23

FIGURE 9



10/23

FIGURE 10




FIGURE 11





FIGURE 12



13/23

FIGURE 13






FIGURE 14



15/23

FIGURE 15A FIGURE 15B FIGURE 15C



16/23

FIGURE 16A



17/23


FIGURE 16B

PLATE NAME: BTC4 PURPOSE: DXM SCREENING

	V134Y	V375Y		V493Y	V513Y	V496Y	
V495Y		V514Y	V508Y		V507Y		V517Y
V518Y	V501Y		V504Y	V494Y	V497Y	V510Y	
	V512Y	V498Y	V502Y	V515Y		V516Y	V499Y
V503Y		V509Y	V519Y		V511Y	V520Y	V506Y
	V508Y	V381Y		V379Y	V560Y	V133Y	


18/23

FIGURE 17A



19/23

FIGURE 17B



20/23

FIGURE 17C**PLATE NAME: BTC6 PURPOSE: DXM SCREENING**

V134Y	V381Y	V494Y	V504Y	V506Y	V512Y	V379Y	V560Y
V134Y	V381Y	V494Y	V504Y	V506Y	V512Y	V379Y	V560Y
V134Y	V381Y	V494Y	V504Y	V506Y	V512Y	V379Y	V560Y
V134Y	V381Y	V494Y	V504Y	V506Y	V512Y	V379Y	V560Y
V134Y	V381Y	V494Y	V504Y	V506Y	V512Y	V379Y	V560Y

FIGURE 18
B-galactosidase activity of V494Y using varying
concentrations of D8M




FIGURE 18
B-galactosidase activity of V494Y using varying
concentrations of D8M






FIGURE 19



23/23

FIGURE 20



INTERNATIONAL SEARCH REPORT

International application No.
PCT/US01/02285

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) :C07K 18/00

US CL :530/387.1; 532/533

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 530/387.1; 532/533

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CAPLUS search terms: cephem, b-lactam, dexamethazone, FK506, methotrexate

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	LICITRA et al. A three-hybrid system for detecting small ligand-protein receptor interactions. Proceedings of the National Academy of Sciences, USA. November 1996, Vol. 93, pages 12817-12821, especially page 12818 compound 4.	1, 11-20, 22-25, 27-32, 44, 60
X	BELSHAW et al. Controlling protein association and subcellular localization with a synthetic ligand that induces heterodimerization of proteins. Proceedings of the National Academy of Sciences, USA. May 1996, Vol. 93, pages 4604-4607, especially page 4605 compound "FkCsA"	1, 11-20, 22-23, 25, 27-32, 44, 60
X	EP 0 742 015 A1 (BRISTOL-MYERS SQUIBB COMPANY) 13 November 1996, Figure 2.	1, 11-22, 27-32

☒ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier document published on or after the international filing date	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"G" document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means	
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

10 APRIL 2001

Date of mailing of the international search report

14 MAY 2001

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

KATHLEEN KERR

Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US01/02285

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5,194,594 A (KWA WLI et al.) 16 March 1993, example 20.	1, 11-20, 22-23, 26-32, 44, 60
A	PEDERSEN et al. A method for directed evolution and functional cloning of enzymes. Proceedings of the National Academy of Sciences, USA. September 1998, Vol. 95, pages 10523-10528.	1, 11-20, 22, 27- 32, 44, 60
A	KLEMM et al. Dimerization as a regulatory mechanism in signal transduction. Annual Review of Immunology. 1998, Vol. 16, pages 569-592.	1, 11-20, 22, 27- 32, 44, 60

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US01/02285

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☒ Claims Nos.: 2-10 and 45-50
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

Upon reconsideration, a meaningful search of Claims 2-10 and 45-50 could not be performed because the recited functional limitations in Claim 2, for example, are not correlated to structural limitations, i.e., a receptor to which the particular H1 and/or H2 bind.

3. ☒ Claims Nos.: 58-59
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.

2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
1, 11-32, 44, and 60

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US01/02285

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional search fees must be paid.

Group I, claim(s) 1, 11-32, 44 and 60, drawn to compounds having a particular formula, compositions thereof, and complexes thereof.

Group II, claim(s) 33-43 and 51-57, drawn to compounds having a particular formula, complexes thereof, and compositions thereof.

Group III, claim(s) 62-68 and 74-82, drawn to methods of screening proteins for the ability to catalyze bond cleavage.

Group IV, claim(s) 69-73 and 74-82, drawn to methods of screening proteins for the ability to catalyze bond formation.

Group V, claim(s) 83, drawn to methods of screening a compound for the ability to inhibit an enzyme.

Group VI, claim(s) 84, drawn to drugs for the inhibition of an enzyme selected by a particular method.

Group VII, claim(s) 85, drawn to methods of evolving a protein with a new catalytic activity.

Group VIII, claim(s) 86, drawn to proteins with new catalytic activity evolved by a particular method.

Group IX, claim(s) 87, drawn to methods of evolving an enzyme with a new substrate specificity.

Group X, claim(s) 88, drawn to engineered enzymes having new substrate specificities screened by a particular method.

Group XI, claim(s) 89, drawn to methods for evolving an enzyme that functions with a cofactor which is different from the cofactor the natural coenzyme uses.

Group XII, claim(s) 90, drawn to engineered enzymes that function with a cofactor which is different from cofactors the enzymes naturally uses evolved by a particular method.

Group XIII, claim(s) 91-124, drawn to compounds having a particular formula and complexes thereof.

Group XIV, claim(s) 125-127, drawn to cells comprising particular complexes.

Group XV, claim(s) 128-132, drawn to methods of dimerizing two fusion proteins inside a cell using a particular compound.

Group XVI, claim(s) 133-137, drawn to methods for identifying a molecule that binds a known target in a cell from a pool of candidate molecules.

Group XVII, claim(s) 138-140, drawn to methods for identifying a protein target to which a molecule is capable of binding.

Groups I, II, XIII, and XIV contain claims directed to more than one species of the generic invention. If Groups I, II, XIII, and/or XIV are elected, a single species of each genus to be examined must also be elected. To specify the species, the particular components, such as identities for H1, X, B, Y, and H2 in the case of Claim 1, or H1, X, and B' in the case of Claim 33, or H1, Y, and H2 in the case of Claim 91 must be identified.

If Groups I, II, XIII, or XIV are elected, an election of species is also required. Applicants are required to elect one species in the genus that is the elected Group. This species will be searched. If this species is free of the prior art, the Examiner will select another species to be examined. This practice will be reiterated until prior art, drawn to any species of the genus, is identified.

If Applicants do not respond to the instant invitation, a search report for Group I, Claims 1-32, 44-50, and 58-60, will be established based solely on a species defined by the Examiner thus possibly rendering certain claims within Group I unsearchable.

The inventions listed as Groups I-XVII do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons.

Group I, drawn to compounds having a particular generic formula, lacks a special technical feature because the technical feature which defines the genus, namely the formula, does not contribute over the prior art. Any antibody is a member of the genus described by the formula in Claim 1.

Because Group I, particularly Claim 1, lacks a special technical feature, no unity of invention can be identified between Group I and any other Group, whether these Groups are other products, such as compounds, drugs, enzymes, or cells, or whether these Groups are methods of making and/or using the products of Group I.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US01/02285

The species listed above do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, the species lack the same or corresponding special technical features for the following reasons.

The broadest claim of each of Groups I, II, XIII and XIV lacks a special technical feature because their respective technical features do not contribute over the prior art. For example, in Claims 1 and 33, any antibody is anticipatory prior art of the genera. For example in Claim 91, and therefore also Claim 125, any methotrexate ("methorexate")-antibody immunoconjugate, such as taught by Elias et al. (see attached Abstract) is anticipatory prior art of the genera.